Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
C-3 NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2017/115329
Kind Code:
A1
Abstract:
The present invention relates to C-3 novel triterpenone derivatives of formula (I); (I) or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, R4, R5, R6, R7, W, ̔m ̕ and ̔n ̕ are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) and process for preparing them, and their use for the treatment of viral diseases and particularly HIV mediated diseases.

More Like This:
WO/2023/018677A THERAPEUTIC COMBINATION COMPRISING A T1GIT ANTAGONIST, A PD-1 ANTAGONIST, AND A CHEMOTHERAPEUTIC AGENT(S)
JP2614407INDUSTRIAL APPLICABILITY: Lipophilic oligosaccharide antibiotic salt composition
JP4527395New cellular target for neurotoxicity
Inventors:
BANDI PARTHASARADHI REDDY (IN)
KURA RATHNAKAR REDDY (IN)
GAZULA LEVI DAVID KRUPADANAM (IN)
ADULLA PANDURANGA REDDY (IN)
KASIREDDY BHASKAR REDDY (IN)
Application Number:
PCT/IB2016/058104
Publication Date:
July 06, 2017
Filing Date:
December 30, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HETERO RESEARCH FOUNDATION (IN)
International Classes:
A61K31/00
Domestic Patent References:
WO2009082818A12009-07-09
WO2011007230A22011-01-20
WO2014105926A12014-07-03
WO2011100308A12011-08-18
Download PDF:
View/Download PDF      PDF Help
Claims:
We claim:

1. A compound of formula (I)

wherein,

Ri is optionally substituted Ci-C6 alkyl,

(wherein

Ra is hydrogen, optionally substituted Ci-C6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R2 at each occurrence are independently selected from hydrogen, alkyl, halo, or haloalkyl;

R3 at each occurrence are independently selected from hydrogen, halo, haloalkyl, alkyl, or -ORt,; wherein R is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, - C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)cycloalkyl, -C(0)arylalkyl, -

HO.

C(0)heterocyclylalkyl, -C(0)cycloalkylalkyl, I , or o ; alternatively, R2 and R3 taken together with the carbon atom to which they are attached form an oxo;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)Rc; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH3)2, -C(0)NH2, -NHC(0)0- alkyl, -N(CH3)C(0)Oalkyl, -N(CH3)alkoxy, -NHC(0)alkyl, -N(CH3)C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R6 together represent an oxo; wherein the optional substituents are independently selected from one or more Rd;

W is absent, -NR8- -NR8(CO)-, -NR8(CR8R8a)i_3- or -NR8S(0)2-;

R7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C6-Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more Re;

R8 and R8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R8 and R8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R8 and R8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more Rd;

Rc is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH3)2, -C(0)OH, -C(0)NH2, hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

Rd is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

Re is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0)2NH2, haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl;

'm' is an integer selected from lor 2; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

2. The compound according to claim 1, is a compound of the formula (IA):

wherein,

Rb is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, -C(0)alkyl, -C(0)aryl optionally substituted with halo, -C(0)arylalkyl, I , or

Ra is hydrogen, optionally substituted Ci-C6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R2 and R3 are independently hydrogen or alkyl;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)Rc; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxyalkylamino, alkoxyalkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH3)2, -C(0)NH2, -NHC(0)0- alkyl, -N(CH3)C(0)Oalkyl, -N(CH3)alkoxy, -NHC(0)alkyl, -N(CH3)C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R6 together represent an oxo; wherein the optional substituents are independently selected from one or more Rd;

W is absent, -NR8- -NR8(CO)-, -NR8(CR8R8a)i_3- or -NR8S(0)2-;

R7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C6-Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more Re;

R8 and R8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R8 and R8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R8 and R8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more Rd;

Rc is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH3)2, -C(0)OH, -C(0)NH2, hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

Rd is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

Re is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0)2NH2, haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

3. The compound according to claim 1, is a compound of the formula (IB):

wherein,

Ri is optionally substituted Ci-C6 alkyl,

(wherein

Ra is hydrogen, optionally substituted Ci-C6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)Rc; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH3)2, -C(0)NH2, -NHC(0)0- alkyl, -N(CH3)C(0)Oalkyl, -N(CH3)alkoxy, -NHC(0)alkyl, -N(CH3)C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R6 together represent an oxo; wherein the optional substituents are independently selected from one or more Rd;

W is absent, -NR8- -NR8(CO)-, -NR8(CR8R8a)i_3- or -NR8S(0)2-;

R7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C6-Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more Re;

R8 and R8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R8 and R8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R8 and R8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more Rd;

Rc is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH3)2, -C(0)OH, -C(0)NH2, hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

Rd is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

Re is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0)2NH2, haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

4. The compound according to claim 1, is a compound of the formula (IC):

wherein, wherein,

optionally substituted Ci-C6 alkyl,

< s RaOOC ,

Ra is hydrogen, optionally substituted Ci-C6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)Rc; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH3)2, -C(0)NH2, -NHC(0)0- alkyl, -N(CH3)C(0)Oalkyl, -N(CH3)alkoxy, -NHC(0)alkyl, -N(CH3)C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl; R5 and R6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R6 together represent an oxo; wherein the optional substituents are independently selected from one or more Rd;

W is absent, -NR8- -NR8(CO)-, -NR8(CR8R8a)i_3- or -NR8S(0)2-;

R7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C6-Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more Re;

R8 and R8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R8 and R8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R8 and R8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more Rd;

Rc is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH3)2, -C(0)OH, -C(0)NH2, hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

Rd is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

Re is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0)2NH2, haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

5. The compound according to claim 1, is a compound of formula (ID)

wherein,

Ra is hydrogen, optionally substituted Ci-C6 alkyl, or optionally substituted C3-C8 cycloalkyl;

R2 at each occurrence are independently selected from hydrogen, alkyl, halo, or haloalkyl;

R3 at each occurrence are independently selected from hydrogen, halo, haloalkyl, alkyl, or -ORb,; wherein Rb is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, - C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)cycloalkyl, -C(0)arylalkyl, -

C(0)heterocyclylalkyl, -C(0)cycloalkylalkyl, , or ; alternatively, R2 and R3 taken together with the carbon atom to which they are attached form an oxo;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)Rc; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH3)2, -C(0)NH2, -NHC(0)0- alkyl, -N(CH3)C(0)Oalkyl, -N(CH3)alkoxy, -NHC(0)alkyl, -N(CH3)C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R6 together represent an oxo; wherein the optional substituents are independently selected from one or more Rd;

W is absent, -NR8- -NR8(CO)-, -NR8(CR8R8a)i_3- or -NR8S(0)2-;

R7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C6-Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more Re;

R8 and R8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R8 and R8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R8 and R8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more Rd;

Rc is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH3)2, -C(0)OH, -C(0)NH2, hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

Rd is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

Re is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0)2NH2, haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl;

'm' is an integer selected from lor 2; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

6. The compound according to claim 1 to 2 and 5, wherein Rb is hydrogen, or optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, -C(0)alkyl, -C(0)aryl, -C(0)arylalkyl, , or

7. The compound according to claim 1 to 5, wherein R4 is hydrogen or optionally substituted alkyl.

8. The compound according to claim 7, wherein the optional substituent are amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, or dialkylaminoalkyl), hydroxy alkylamino, alkoxyalkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH3)2, - C(0)NH2, -NHC(0)Oalkyl, -N(CH3)C(0)Oalkyl, -N(CH3)alkoxy, -NHC(0)alkyl, - N(CH3)C(0)alkyl, -C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, or -C(0)heterocyclyl.

9. A compound selected from the group consisting of:

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4

chlorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- ((phenylmethyl-d2)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((R)-l- phenylethyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4- chlorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((2- phenylpropan-2-yl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((S)-l- phenylethyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(benzylamino)-l- hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((3- chlorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- chlorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4- fluorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((3,4- dichlorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((3-chlorobenzyl)(2- (dimethylamino)ethyl)amino)- 1-hydroxyethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2-chlorobenzyl)(2- (dimethylamino)ethyl)amino)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- methylbenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- methoxybenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- (methylsulfonyl)benzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((pyridin-2 ylmethyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((pyridin-4 ylmethyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- (trifluoromethyl)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(4- methyl-lH-imidazol-l-yl)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((pyridin-3 ylmethyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((5-chloropyridin-2- yl)methyl)amino)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((6- methylpyridin-3-yl)methyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((2- morpholinopyridin-3-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentameth^ 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- (dimethylamino)ethyl)((6-methylpyrazin-2-yl)methyl)amino)-l-hydroxyeth

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- (dimethylamino)ethyl)(pyrimidin-5-ylmethyl)amino)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((6-aminopyridin-3- yl)methyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- ((pyrimidin-2-ylmethyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- (dimethylamino)ethyl)(pyrimidin-4-ylmethyl)amino)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- (dimethylamino)ethyl)(thiazol-2-ylmethyl)amino)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((2,4-dimethylthiazol- 5-yl)methyl)amino)- 1 -hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((l- methyl- lH-imidazol-2-yl)methyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((3- methyl- lH-pyrazol-5-yl)methyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((3,5- dimethylisoxazol-4-yl)methyl)amino)-l -hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((2-aminothiazol-4- yl)methyl)amino)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((lH-imidazol-2- yl)methyl)amino)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- (dimethylamino)ethyl)((3-isopropyl-lH^

isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2- (dimethylamino)ethyl)((5-methyl-l,3,4-oxadiazol-2-yl)methyl)amino)-l-hydrox isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((2,5-dimethylfuran 3-yl)methyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((lH- benzo[d]imidazol-2-yl)methyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((2- phenyl-lH-benzo[d]imidazol-6-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((2- methyl- lH-benzo[d]imidazol-6-yl)methyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- ((pyrazolo[l,5-a]pyrimidin-3-ylmethyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((lH- benzo[d]imidazol-6-yl)methyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(((2-(6- methylpyridin-3-yl)-lH-benzo[d]imidazol-6-yl)methyl)amino)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((quinolin- 2-ylmethyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- morpholinobenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(4- methylpiperazin-l-yl)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-(l,l- dioxidothiomorpholino)benzyl)amino)- 1-hydroxyethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,H

dioxidothiomorpholino)methyl)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8 pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- (piperidin-l-yl)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(4- hydroxypiperidin-l-yl)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((6-(l,l- dioxidothiomorpholino)pyridin-3-yl)methyl)arnino)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-((4- hydroxypiperidin- 1 - yl)methyl)benzyl) amino)ethyl) - 1 -isopropyl-5 a, 5b , 8 , 8 , 11 a-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4- (morpholinomethyl)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(4- morpholinopiperidin-l-yl)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2 oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(2- morpholinoethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(((R)- tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-((4- methylpiperazin-l-yl)methyl)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentameth oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(5- methyl-l,3,4-oxadiazol-2-yl)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(2- methoxyethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((4-(((S)- tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2- methoxybenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(2- methoxyethoxy)benzyl)amino)- 1 -hydroxy ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2- (piperidin-4-yloxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2 oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(2- morpholinoethoxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2 oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(2- (dimethylamino)ethoxy)benzyl)amino)- 1 -hydroxy ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2-amino-2- methylpropyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((2- (piperidin- l-yl)ethyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((2- morpholinoethyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4-chloro-2-(2- (piperidin-l-yl)ethoxy)benzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2-(4-ethylpiperazin- l-yl)ethyl)amino)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2-(l,l- dioxidothiomorpholino)ethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((piperidin- 4-ylmethyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((((S)- pyrrolidin-2-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((((S)- piperidin-3-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((((R)- piperidin-2-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- ((cyclohexylmethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(((S)-2-amino-3- methylbutyl)amino)- 1 -hydroxy ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((((R)- piperidin-3-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((((S)- piperidin-2-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((4- chlorophenethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- ((cyclopropylmethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- ((cyclopentylmethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- ((cyclobutylmethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2-(5- chloropyrimidin-2-yl)propan-2-yl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((benzo[d][l,3]dioxol- 5-ylmethyl)amino)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chlorobenzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chlorobenzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-benzamido-l- hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3-chlorobenzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-chlorobenzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-fluorobenzamido) 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- methoxybenzamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- (methylsulfonyl)benz amido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- (picolinamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- (isonicotinamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(6- methylnicotinamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2- morpholinonicotinamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(N-(2- (dimethylamino)ethyl)-6-methylpyrazine-2-carboxamido)-l-hydroxyethyl)-l-isop

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadeca ydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(N-(2- (dimethylamino)ethyl)pyrimidine-5-carboxamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2,4-dimethylthiazole 5-carboxamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(l-methyl- lH-imidazole-2-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(3-methyl- lH-pyrazole-5-carboxamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3,5- dimethylisoxazole-4-carboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2,5-dimethylfuran-3- carboxamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(lH- benzo[d]imidazole-2-carboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-phenyl- lH-benzo[d]imidazole-6-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- lH-benzo[d]imidazole-6-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- morpholinobenzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(4- methylpiperazin-l-yl)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-(l,l- dioxidothiomorpholino)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentam 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-((l,l- dioxidothiomorpholino)methyl)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- (morpholinomethyl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(4- morpholinopiperidin- l-yl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(2- morpholinoethoxy)benzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2- methoxybenzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(2- methoxyethoxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(piperidin- 4-yloxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-amino-2- methylpropanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2- (piperidin- l-yl)acetamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2- morpholinoacetamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((S)- pyrrolidine-2-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((S)- piperidine-3-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((R)- piperidine-2-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- (cyclohexanecarboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- (cyclopropanecarboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- (cyclopentanecarboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-N-(2- (dimethylamino)ethyl)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl^ 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-N-(2- (dimethylamino)ethyl)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3,4- dichlorobenzamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3-chloro-N-(2- (dimethylamino)ethyl)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-chloro-N-(2- (dimethylamino)ethyl)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentameth 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- methylbenzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- (trifluoromethyl )benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(4- methyl- lH-imidazol- l-yl)benzamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- (nicotinamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(5- chloropicolinamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(6- aminonicotinamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- (pyrimidine-2-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(N-(2- (dimethylamino)ethyl)pyrimidine-4-carboxamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(N-(2- (dimethylamino)ethyl)thiazole-2-carboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,i pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-aminothiazole-4- carboxamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(lH- imidazole-2-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(N-(2- (dimethylamino)ethyl)-3-isopropyl- lH-pyrazole-5-carboxamido)- 1-hydroxyethyl)- 1- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(N-(2- (dimethylamino)ethyl)-5-methyl-l,3,4-oxadiazole-2-carboxamido)-l-hydroxyethyl^ isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- (pyrazolo[l,5-a]pyrimidine-3-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(lH- benzo[d]imidazole-6-carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-(6- methylpyridin-3-yl)-lH-benzo[d]imidazole-6-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(quinoline- 2-carboxamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4- (piperidin- l-yl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(4- hydroxypiperidin- l-yl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(6-(l,l- dioxidothiomorpholino)nicotinamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-((4- hydroxypiperidin-l-yl)methyl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-((4- methylpiperazin-l-yl)methyl)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(5- methyl-l,3,4-oxadiazol-2-yl)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(2- methoxyethoxy)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(4-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l l^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(2- morpholinoethoxy )benzamido) - 1 -hydroxyethyl) - 1 -isopropyl- 5a,5b,8,8,l l a-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(2- (dimethylamino)ethoxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b,8,8,l la-pentamethyl 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(4-chloro-2-(2- (piperidin-l-yl)ethoxy)benzamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-ethylpiperazin-l yl)acetamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(l,l- dioxidothiomorpholino)acetamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, 1 la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(piperidine 4-carboxamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((S)-2-amino-3- methylbutanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((R)- piperidine-3-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-((S)- piperidine-2-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4- chlorophenyl)acetamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2- (cyclobutanecarboxamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2- pivalamidoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4- chlorobenzamido)acetamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4- chlorobenzamido)-2,2-difluoroacetamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(2-(4- chlorobenzamido)-2-fluoroacetamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((S)-2-(4- chlorobenzamido)propanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, l la-pentamethyl-2 oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l-(4- chlorobenzamido)cyclobutane- l-carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3-(4- chlorobenzamido)azetidine-3-carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l-(4- chlorobenzamido)cyclohexane- l-carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b,8,8, 11a pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((S)-2-(4- chlorobenzamido)-3 -hydroxypropanamido) - 1 -hydroxy ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11a- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2S,3R)-2-(4- chlorobenzamido)-3-hydroxybutanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(4-amino-2-(4- chlorobenzamido)butanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(6-amino-2-(4- chlorobenzamido)hexanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(2-(4- chlorobenzamido)-3-hydroxybutanamido-2-d)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(4-amino-2-(4- chlorobenzamido)butanamido-2-d)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(6-amino-2-(4- chlorobenzamido)hexanamido-2-d)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(2-(4- chlorobenzamido)-3-hydroxy-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(3-amino-2-(4- chlorobenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(5-amino-2-(4- chlorobenzamido)-2-methylpentanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(3- chlorobenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(2- chlorobenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4- fluorobenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-(4- methoxybenzamido)-2-methylpropanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2 oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(methylsulfonyl)benzamido )propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(picolinamido)propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2- (isonicotinamido)-2-methylpropanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(6-methylnicotinamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(pyrimidine-2-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2 oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(6-methylpyrazine-2-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(thiazole-2-carboxamido)propanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(2-aminothiazole-4- carboxamido)-2-methylpropanamido)-l -hydroxy ethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(lH-imidazole-2- carboxamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-(3- isopropyl-lH-pyrazole-5-carboxamido)-2-methylpropanamido)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(lH- benzo[d]imidazole-2-carboxamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(2-methyl-lH-benzo[d]imidazole-6-carboxamido)propanamido)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-morpholinobenzamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(4-methylpiperazin- l-yl)benzamido)propanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-(l,l- dioxidothiomorpholino)benzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(2-morpholinoethoxy)benzamido)propanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzamido)propanamido)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(2- methoxyethoxy)benzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 - isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(2- (dimethylamino)ethoxy)benzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(2- (piperidin- 1 -yl)ethoxy)benzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(2-(piperidin-l-yl)acetamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(2-(l,l- dioxidothiomorpholino)acetamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l- aminocyc lopropane-l-carboxamido)-l -hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l-aminocyclohexane- 1-carboxamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3-aminoazetidine-3- carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4- chlorobenzamido)acetamido-2,2-d2-2,2-d2)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(2-(4- chlorobenzamido)acetamido-2-d-d)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((R)-2-(4- chlorobenzamido)propanamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8, 8, l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l-(4- chlorobenzamido)cyclopropane-l -carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(3-(4- chlorobenzamido)oxetane-3-carboxamido)- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l-(4- chlorobenzamido)cyclopentane- 1 -carboxamido)- 1-hydroxyethyl)- 1 -isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((R)-2-(4- chlorobenzamido)-3 -hydroxypropanamido) - 1 -hydroxy ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11a- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-((2R,3S)-2-(4- chlorobenzamido)-3-hydroxybutanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(3-amino-2-(4- chlorobenzamido)propanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(5-amino-2-(4- chlorobenzamido)pentanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(2-(4- chlorobenzamido)-3-hydroxypropanamido-2-d)- 1 -hydroxy ethyl)- 1 -isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(3-amino-2-(4- chlorobenzamido)propanamido-2-d)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(5-amino-2-(4- chlorobenzamido)pentanamido-2-d)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(3-amino-2-(4- chlorobenzamido)-2-fluoropropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(5-amino-2-(4- chlorobenzamido)-2-fluoropentanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(2-(4- chlorobenzamido)-3-hydroxy-2-methylbutanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(4-amino-2-(4- chlorobenzamido)-2-methylbutanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((lR)-2-(6-amino-2-(4- chlorobenzamido)-2-methylhexanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(2- chlorobenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(3,4- dichlorobenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-methylbenzamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(trifluoromethyl)benzamido)propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(4-methyl-lH-imidazol-l-yl)benzamido)propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(nicotinamido)propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-((R)- l-hydroxy-2-(2-methyl- 2-(5-methylpicolinamido)propanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(6- aminonicotinamido)-2-methylpropanarrddo)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(pyrimidine-4-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(pyrimidine-5-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(2,4- dimethylthiazole-5-carboxamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isoprop 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(l-methyl-lH-imidazole-2-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl 2-(3-methyl- lH-pyrazole-5-carboxamido)propanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(3,5- dimethylisoxazole-4-carboxamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(lH- benzo[d]imidazole-6-carboxamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl 2-(quinoline-2-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl 2-(4-(piperidin-l-yl)benzamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-(4-(4- hydroxypiperidin-l-yl)benzamido)-2-methylpropanamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl 2-(4-(morpholinomethyl)benzamido)propanamido)ethyl)- 1 -isopropyl-5 a,5b ,8 , 8,11a- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl- 2-(4-(((R)-tetrahydrofuran-3-yl)oxy)benzamido)propanamido)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2- methoxybenzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(2- morpholinoethoxy)benzamido)-2-methylpropanamido)- 1 -hydroxy ethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(4-chloro-2- (piperidin-4-yloxy)benzamido)-2-methylpropanamido)-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-((R)-2-(2-(4-chloro-2-(2- (pyrrolidin- 1 -yl)ethoxy)benzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(2-(2- (dimethylamino)acetamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadeca ydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl 2-(2-morpholinoacetamido)propanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl 2-(piperidine-4-carboxamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-(l-aminocyclobutane-

1- carboxamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-((R)-2-(3-aminooxetane-3- carboxamido)- l-hydroxyethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-l-hydroxy-2-(2-methyl-

2- (6-methylpicolinamido)propanamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((benzo[d][l,3]dioxol-5- ylmethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chlorobenzyl)amino)- 2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-chlorobenzyl)amino)- 2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((l-(4- chlorophenyl)cyclopropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR, l lbR,13aS)-3a-(2-((l-(4- chlorophenyl)cyclopentyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-(4- chlorophenyl)oxetan-3-yl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((phenylmethyl-d2)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-(((R)-l-phenylethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chlorobenzyl)amino)- 2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(benzylamino)-2- oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-chlorobenzyl)(2- (dimethylamino)ethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-fluorobenzyl)amino)-2- oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((4- methoxybenzyl)amino)-2-oxoethyl)-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(methylsulfonyl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((pyridin-2-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((pyridin-4-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((6-methylpyridin-3-yl)methyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((2-morpholinopyridin-3-yl)methyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)((6-methylpyrazin-2-yl)methyl)amino)-2-oxoethyl)-l-isopropyl^ 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)(pyrim

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2,4-dimethylthiazol-5- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((l-methyl-lH-imidazol-2-yl)methyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((3-methyl-lH-pyrazol-5-yl)methyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3,5-dimethylisoxazol-4- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2,5-dimethylfuran-3- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((lH-benzo[d]imidazol-2- yl)methyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3 a-(2-oxo-2-(((2-phenyl- 1 H-benzo [d] imidazol-6-yl)methyl)amino)ethyl) - 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((2-methyl-lH-benzo[d]imidazol-6-yl)methyl)amino)-2-oxoethyl)-2- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-morpholinobenzyl)arnino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(4-methylpiperazin-l-yl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-(l,l- dioxidothiomorpholino)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentameth oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-((l,l- dioxidothiomorpholino)methyl)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l l^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(morpholinomethyl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(4-morpholinopiperidin-l-yl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(2-morpholinoethoxy)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((4-(((R)-tetra ydrofuran-3-yl)oxy)benzyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2- methoxybenzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- methoxyethoxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(piperidin-4- yloxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-amino-2- methylpropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((2-(piperidin-l-yl)ethyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-morpholinoethyl)amino)-2-oxoethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((((S)-pyrrolidin-2-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((((S)-piperidin-3-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((((R)-piperidin-2-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclohexylmethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclopropylmethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclopentylmethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((l-(5-chloropyrimidin-2- yl)cyclopropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((2-phenylpropan-2-yl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-chlorobenzyl)amino)- 2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4- chlorophenyl)propan-2-yl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((l-(4- chlorophenyl)cyclobutyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((l-(4- chlorophenyl)cyclohexyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-(4- chlorophenyl)azetidin-3-yl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((difluoro(phenyl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-(((S)-l-phenylethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((2-phenylpropan-2-yl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3,4- dichlorobenzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-chlorobenzyl)(2- (dimethylamino)ethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-methylbenzyl)amino)-2-oxoethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((4-(trifluoromethyl)benzyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(4-methyl-lH-imidazol-l-yl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((pyridin-3-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((5-chloropyridin-2- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((6-aminopyridin-3- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((pyrimidin-2-ylmethyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)(pyrimidin-4-ylmethyl)amino)-2-oxoethyl)-l-isoprop

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)(thiazol-2-ylmethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2-aminothiazol-4- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((lH-imidazol-2- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)((3-isopropyl-lH-pyrazol-5-yl)methyl)amino)-2-oxoethyl)-l- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)((5-methyl-l,3,4-oxadiazol-2-yl)methyl)amino)-2-oxoethyl)-l- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3 a-(2-oxo-2-((pyrazolo [ 1 ,5 -a]pyrimidin-3 -ylmethyl)amino)ethyl) - 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((lH-benzo[d]imidazol-6 yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((2-(6-methylpyridin-3-yl)-lH-benzo[d]imidazol-6-yl)methyl)amino)^ oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((quinolin-2-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((4-(piperidin-l-yl)benzyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-(4-hydroxypiperidin-l yl)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,HbR,13aS)-3a-(2-(((6-(l,l- dioxidothiomorpholino)pyridin-3-yl)m

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-((4-hydroxypiperidin- l-yl)methyl)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-((4-methylpiperazin-l-yl)methyl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(5-methyl-l,3,4-oxadiazol-2-yl)benzyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((4-(2- methoxyethoxy)benzyl)amino)-2-oxoethyl)-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- morpholinoethoxy)benzyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- (dimethylamino)ethoxy)benzyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2-(piperidin- l-yl)ethoxy)benzyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-ethylpiperazin-l- yl)ethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(l,l- dioxidothiomorpholino)ethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR, 13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((piperidin-4-ylmethyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((S)-2-amino-3- methylbutyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((((R)-piperidin-3-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-oxo-2-((((S)-piperidin-2-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4- chlorophenethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclobutylmethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(5-chloropyrimidin-2- yl)propan-2-yl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4- chlorobenzamido)ethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 2,2-difluoroethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 2-fluoroethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((S)-2-(4- chlorobenzamido)propyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclobutyl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-(4- chlorobenzamido)azetidin-3-yl)methyl)arnino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclohexyl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((R)-2-(4- chlorobenzamido)-3-hydroxypropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2R,3R)-2-(4- chlorobenzamido)-3-hydroxybutyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)butyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((6-amino-2-(4- chlorobenzamido)hexyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 3-hydroxybutyl-2-d)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)butyl-2-d)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((6-amino-2-(4- chlorobenzamido)hexyl-2-d)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 2-fluoro-3-hydroxybutyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)-2-fluorobutyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-

2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)-

3- hydroxy-2-methylpropyl)arnino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)-2-methylpentyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(3-chlorobenzamido)- 2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-chlorobenzamido)- 2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-fluorobenzamido)-2- methylpropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((2-(4- methoxybenzamido)-2-methylpropyl)amino)-2-oxoethyl)-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(methylsulfonyl)benzamido)propyl)amino)-2-oxoethyl) 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(picolinamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(isonicotinamido)-2- methylpropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(6-methylnicotinamido)propyl)amino)-2-oxoethyl)-2-o 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(pyrim

oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(6-methylpyrazine-2-carboxamido)propyl)amino)-2- oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(thiazole-2-carboxamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-aminothiazole-4- carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(lH-imidazole-2- carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((2-(3- isopropyl- lH-pyrazole-5-carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(lH- benzo[d]imidazole-2-carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(2-methyl-lH-benzo[d]imidazole-6- carboxamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,H

pentamethyl-3a-(2-((2-methyl-2-(4-morpholinobenzamido)propyl)amino)-2-oxoethyl)-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(4-methylpiperazin-l-yl)benzamido)propyl)amino)-2 oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-(l,l- dioxidothiomorpholino)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopr^

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(2-morpholinoethoxy)benzamido)propyl)amino)-2- oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(((S)-tetrahydrofuran-3- yl)oxy)benzamido)propyl)amino)-2-oxoethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- methoxyethoxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzamido)-2-methylpropyl)amino)-2-oxoeth

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb,12,13, 13a- octadeca ydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- (dimethylamino)ethoxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopro

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- (piperidin-l-yl)ethoxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(2-(piperidin-l-yl)acetamido)propyl)amino)-2-oxoethyl)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-(l,l- dioxidothiomorpholino)acetamido)-2-methylpropyl)amino)-2-oxoethyl)-l-i

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l- aminocyclopropyl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l- aminocyclohexyl)methyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-aminoazetidin-3- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(benzo[d][l,3]dioxole- 5-carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((R)-2-(4- chlorobenzamido)propyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclopropyl)methyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-(4- chlorobenzamido)oxetan-3-yl)methyl)arnino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclopentyl)methyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((S)-2-(4- chlorobenzamido)-3-hydroxypropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2S,3S)-2-(4- chlorobenzamido)-3-hydroxybutyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)propyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)pentyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 3-hydroxypropyl-2-d)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)propyl-2-d)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)pentyl-2-d)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR, l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 2-fluoro-3-hydroxypropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)-2-fluoropropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)-2-fluoropentyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 3-hydroxy-2-methylbutyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)-2-methylbutyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((6-amino-2-(4- chlorobenzamido)-2-methylhexyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-chlorobenzamido)- 2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(3,4- dichlorobenzamido)-2-methylpropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-methylbenzamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(trifl^

2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(4-methyl-lH-imidazol-l-yl)benzamido)propyl)amino oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(nicotinamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(5-methylpicolinamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(6- aminonicotinamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(pyrimidine-4-carboxamido)propyl)amino)-2-oxoethy oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(pyrimidine-5-carboxamido)propyl)amino)-2-oxoethy oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2,4-dimethylthiazole- 5-carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(l-methyl-lH-imidazole-2-carboxamido)propyl)amino)- oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(3-methyl-lH-pyrazole-5-carboxamido)propyl)amino)-2- oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(3,5- dimethylisoxazole-4-carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(lH- benzo[d]imidazole-6-carboxamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(quinoline-2-carboxamido)propyl)arrdno)-2-oxoethyi oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(piperidin-l-yl)benzamido)propyl)amino)-2-oxoethyl)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-(4- hydroxypiperidin-l-yl)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(morpholinomethyl)benzamido)propyl)amino^ oxoethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(((R)-tetrahydrofuran-3- yl)oxy)benzamido)propyl)amino)-2-oxoethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2- methoxybenzamido)-2-methylpropyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- morpholinoethoxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(piperidin- 4-yloxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2- (dimethylamino)acetamido)-2-methylpropyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(2-morpholinoacetamido)propyl)amino)-2-oxoethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(piperidine-4-carboxamido)propyl)amino)-2-oxoethyl)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l- aminocyclobutyl)methyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-aminooxetan-3- yl)methyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(6-methylpicolinamido)propyl)amino)-2-oxoethyl)-2-ox 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((benzo[d][l,3]dioxol-5- ylmethyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((phenylmethyl-d2)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(((R)-l-phenylethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4- chlorobenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((2-phenylpropan-2-yl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((difluoro(phenyl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(((S)-l-phenylethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((2-phenylpropan-2-yl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(benzylamino)ethyl)-l- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3- chlorobenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- chlorobenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4- fluorobenzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3,4- dichlorobenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-chlorobenzyl)(2- (dimethylamino)ethyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-methylbenzyl)amino)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((4- methoxybenzyl)amino)ethyl)-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(methylsulfonyl)benzyl)amino)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((pyridin-2-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((pyridin-4-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((4-(trifluoromethyl)benzyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(4-methyl-lH-imidazol-l-yl)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((pyridin-3-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((5-chloropyridin-2- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((6-methylpyridin-3-yl)methyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((2-morpholinopyridin-3-yl)methyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)((6-methylpyrazin-2-yl)methyl)amino)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)(pyrim

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((6-aminopyridin-3- yl)methyl)amino)ethyl)- 1 -isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((pyrimidin-2-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)(pyrimidin-4-ylmethyl)amino)ethyl)-l-isopropyl-5a,^

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)(thiazol-2-ylmethyl)amino)ethyl)-l-isopropyl-5a,5b,8,8 ,11a- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2,4-dimethylthiazol-5- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((l-methyl-lH-imidazol-2-yl)methyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((3-methyl-lH-pyrazol-5-yl)methyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3,5-dimethylisoxazol-4- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2-aminothiazol-4- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((lH-imidazol-2- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)((3-isopropyl-lH-pyrazol-5-yl)methyl)amino)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2- (dimethylamino)ethyl)((5-methyl-l,3,4-oxadiazol-2-yl)methyl)amino)ethyl)-l^

5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2,5-dimethylfuran-3- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((lH-benzo[d]imidazol-2 yl)methyl)amino)ethyl)- 1 -isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(((2 -phenyl- lH-benzo[d]imidazol-6-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((2-methyl-lH-benzo[d]imidazol-6-yl)methyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((pyrazolo[l,5-a]pyrimidin-3-ylmethyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((lH-benzo[d]imidazol-6 yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(((2-(6-methylpyridin-3-yl)-lH-benzo[d]imidazol-6- yl)methyl)amino)ethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((quinolin-2-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-morpholinobenzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(4-methylpiperazin-l-yl)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-(l,l- dioxidothiomorpholino)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-((l,l- dioxidothiomorpholino)methyl)ben^

2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((4-(piperidin-l-yl)benzyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-(4-hydroxypiperidin- yl)benzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((6-(l,l- dioxidothiomorpholino)pyridin-3-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-((4-hydroxypiperidin- l-yl)methyl)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(morpholinomethyl)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(4-morpholinopiperidin-l-yl)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(2-morpholinoethoxy)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((4-(((R)-tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-((4-methylpiperazin-l-yl)methyl)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((4-(5-methyl-l,3,4-oxadiazol-2-yl)benzyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((4-(2- methoxyethoxy )benzyl) amino)ethyl) - 5a,5b,8,8,l l a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2- methoxybenzyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- methoxyethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(piperidin-4- yloxy)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- morpholinoethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- (dimethylamino)ethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-amino-2- methylpropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((2-(piperidin-l-yl)ethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-morpholinoethyl)amino)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-chloro-2-(2-(piperidin- l-yl)ethoxy)benzyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-ethylpiperazin-l- yl)ethyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(l,l- dioxidothiomorpholino)ethyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((piperidin-4-ylmethyl)amino)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((((S)-pyrrolidin-2-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((((S)-piperidin-3-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((((R)-piperidin-2-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclohexylmethyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((S)-2-amino-3- methylbutyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((((R)-piperidin-3-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((((S)-piperidin-2-yl)methyl)amino)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4- chlorophenethyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclopropylmethyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclopentylmethyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((l-(5-chloropyrimidin-2- yl)cyclopropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((cyclobutylmeth yl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(5-chloropyrimidin-2- yl)propan-2-yl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chlorobenzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- chlorobenzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-benzamidoethyl)-l- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(3- chlorobenzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2- chlorobenzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4- fluorobenzamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-(4- methoxybenzamido)ethyl)-5a,5b,8,8, 1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(methylsulfonyl)benzamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(picolinamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(isonicotinamido)ethyl)-l- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(6-methylnicotinamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(2-morpholinonicotinamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(N-(2- (dimethylamino)ethyl)-6-methylpyrazine-2-carboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(N-(2- (dimethylamino)ethyl)pyrimidine-5-carboxamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2,4-dimethylthiazole-5- carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(l-methyl-lH-imidazole-2-carboxamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(3-methyl-lH-pyrazole-5-carboxamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(3,5-dimethylisoxazole-4 carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2,5-dimethylfuran-3- carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(lH-benzo[d]imidazole-2- carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(2-phenyl-lH-benzo[d]imidazole-6-carboxamido)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(2-methyl-lH-benzo[d]imidazole-6-carboxamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-morpholinobenzamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(4-methylpiperazin-l-yl)benzamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-(l,l- dioxidothiomorpholino)benzamido)ethyl) - 1 -isopropyl-5a,5b ,8 , 8,11 a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-((l,l- dioxidothiomorpholino)methyl)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-^

oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(morpholinomethyl)benzamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(4-morpholinopiperidin-l-yl)benzamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(2-morpholinoethoxy)benzamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(4-(((R)-tetrahydrofuran-3-yl)oxy)benzamido)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2- methoxybenzamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- methoxyethoxy)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(piperidin-4- yloxy)benzamido)ethyl) - 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-(pyrrolidin- l-yl)ethoxy)benzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-acetamidoethyl)-l- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(2-(piperidin-l-yl)acetamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(2-morpholinoacetamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((S)-pyrrolidine-2-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((S)-piperidine-3-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((R)-piperidine-2-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (cyclohexanecarboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (cyclopropanecarboxamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (cyclopentanecarboxamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-N-(2- (dimethylamino)ethyl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lS,3R)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-N-(2- (dimethylamino)ethyl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(3,4- dichlorobenzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(3-chloro-N-(2- (dimethylamino)ethyl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-chloro-N-(2- (dimethylamino)ethyl)benzamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-methylbenzamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(4-(trifluoromethyl)benzamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(4-methyl-lH-imidazol-l-yl)benzamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(nicotinamido)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(5- chloropicolinamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(6- aminonicotinamido)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(pyrimidine-2-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(N-(2- (dimethylamino)ethyl)pyrimidine-4-carboxamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(N-(2- (dimethylamino)ethyl)thiazole-2-carboxamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentam 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-aminothiazole-4- carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(lH-imidazole-2- carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(N-(2- (dimethylamino)ethyl)-3-isopropyl- lH-pyrazole-5-carboxamido)ethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(N-(2- (dimethylamino)ethyl)-5-methyl-l,3,4-oxadiazole-2-carboxamido)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(pyrazolo[l,5-a]pyrimidine-3-carboxamido)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(lH-benzo[d]imidazole-6- carboxamido)ethyl)- 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(2-(6-methylpyridin-3-yl)-lH-benzo[d]imidazole-6-carboxamido)ethyl)-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(quinoline-2-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(4-(piperidin-l-yl)benzamido)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadeca ydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-(4-hydroxypiperidin-l yl)benzamido)ethyl) - 1 -isopropyl-5 a,5b, 8 ,8 , 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(6-(l,l- dioxidothiomorpholino)nicotinamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-((4-hydroxypiperidin- yl)methyl)benzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-((4-methylpiperazin-l-yl)methyl)benzamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-(4-(5-methyl-l,3,4-oxadiazol-2-yl)benzamido)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-(4-(2- methoxyethoxy)benzamido)ethyl)-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzamido)ethyl)- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid ( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-(2-(4-chloro-2-(2-( 1,1- dioxidothiomorpholino)ethoxy)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentameth oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- morpholinoethoxy)benzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-(2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2- (dimethylamino)ethoxy)benzamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(4-chloro-2-(2-(piperidin l-yl)ethoxy)benzamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-(4-ethylpiperazin-l- yl)acetamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-(l,l- dioxidothiomorpholino)acetamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-(piperidine-4-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((S)-2-amino-3- methylbutanamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((R)-piperidine-3-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-((S)-piperidine-2-carboxamido)ethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-(4- chlorophenyl)acetamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (cyclobutanecarboxamido)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-2-oxo-3a-(2-pivalamidoethyl)-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4- chlorobenzamido)ethyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido) 2,2-difluoroethyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 2-fluoroethyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((S)-2-(4- chlorobenzamido)propyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclobutyl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-(4- chlorobenzamido)azetidin-3-yl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamet^ 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclohexyl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((R)-2-(4- chlorobenzamido)-3-hydroxypropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2R,3R)-2-(4- chlorobenzamido)-3-hydroxybutyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)butyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((6-amino-2-(4- chlorobenzamido)hexyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 3-hydroxybutyl-2-d)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)butyl-2-d)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((6-amino-2-(4- chlorobenzamido)hexyl-2-d)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)-

2- fluoro-3-hydroxybutyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)-2-fluorobutyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)-

3- hydroxy-2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)-2-methylpentyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(3-chlorobenzamido)- 2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-chlorobenzamido)- 2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-fluorobenzamido)- 2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((2-(4- methoxybenzamido)-2-methylpropyl)amino)ethyl)-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)

pentamethyl-3a-(2-((2-methyl-2-(4-(methylsulfonyl)benzamido)propyl)amino)ethyl)-2-oxo 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(picolinamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(isonicotinamido)-2- methylpropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(6-methylnicotinamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(pyrimidine-2-carboxamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(6-methylpyrazine-2-carboxamido)propyl)amino)ethyl^ oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(thiazole-2-carboxamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-aminothiazole-4- carboxamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(lH-imidazole-2- carboxamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-3a-(2-((2-(3- isopropyl-lH-pyrazole-5-carboxamido)-2-methylpropyl)amino)ethyl)-5a,5b,8,8,l la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(lH- benzo[d]imidazole-2-carboxamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l l pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(2-methyl-lH-benzo[d]imidazole-6- carboxamido)propyl)amino)ethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-morpholinobenzamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(4-m

2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-(l,l- dioxidothiomorpholino)benzamido)-2-m

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(2-m

oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(((S)-tetrahydrofuran-3- yl)oxy)benzamido)propyl)amino)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- methoxyethoxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2-(l,l- dioxidothiomorpholino)ethoxy)benzamido)-2-methylpropyl)amino)ethyl)-i 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(((S)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- (dimethylamino)ethoxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- (piperidin-l-yl)ethoxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l l^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(2-(piperidin-l-yl)acetamido)propyl)arrdno)ethyl)-2-o 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-(l,l- dioxidothiomorpholino)acetamido)-2-methylpropyl)amino)ethyl)-l-isopr^

pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l- aminocyclopropyl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l- aminocyclohexyl)methyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-aminoazetidin-3- yl)methyl)amino)ethyl)- 1 -isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(benzo[d][l,3]dioxole- 5-carboxamido)-2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((R)-2-(4- chlorobenzamido)propyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclopropyl)methyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-(4- chlorobenzamido)oxetan-3-yl)methyl)arnino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorobenzamido)cyclopentyl)methyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((S)-2-(4- chlorobenzamido)-3-hydroxypropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((2S,3S)-2-(4- chlorobenzamido)-3-hydroxybutyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)propyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)pentyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido) 3-hydroxypropyl-2-d)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)propyl-2-d)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)pentyl-2-d)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido) 2-fluoro-3-hydroxypropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((3-amino-2-(4- chlorobenzamido)-2-fluoropropyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((5-amino-2-(4- chlorobenzamido)-2-fluoropentyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chlorobenzamido)- 3-hydroxy-2-methylbutyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4-amino-2-(4- chlorobenzamido)-2-methylbutyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((6-amino-2-(4- chlorobenzamido)-2-methylhexyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2-chlorobenzamido)- 2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(3,4- dichlorobenzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethy oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-methylbenzamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)

pentamethyl-3a-(2-((2-methyl-2-(4-(trifluoromethyl)benzamido)propyl)amino)eth

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(4-methyl-lH-imidazol-l- yl)benzamido)propyl)amino)ethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(nicotinamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(5-methylpicolinamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(6- aminonicotinamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentametn oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(pyrimidine-4-carboxamido)propyl)amino)ethyl)-2-ox 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(pyrimidine-5-carboxamido)propyl)amino)ethyl)-2- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

( lR,3S)-3-((((3aR,5aR,5bR,7aR,9S, 1 laR, 1 IbR, 13aS)-3a-(2-((2-(2,4-dimethylthiazole- 5-carboxamido)-2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(l-methyl-lH-imidazole-2- carboxamido)propyl)amino)ethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a- octadeca ydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(l-methyl-lH-imidazole-2- carboxamido)propyl)amino)ethyl)-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(3,5- dimethylisoxazole-4-carboxamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l ^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(lH- benzo[d]imidazole-6-carboxamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(quinoline-2-carboxamido)propyl)arrdno)ethyl)-2- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(piperidin-l-yl)benzamido)propyl)arnino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1 -carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-(4- hydroxypiperidin-l-yl)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(m

oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(4-(((R)-tetrahydrofuran-3- yl)oxy)benzamido)propyl)amino)ethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2- methoxybenzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- morpholinoethoxy)benzamido)-2-methylpropyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(((R)- tetrahydrofuran-3-yl)oxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l- carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(piperidin- 4-yloxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(4-chloro-2-(2- (pyrrolidin-l-yl)ethoxy)benzamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,l la^ pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la, 1 lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((2-(2- (dimethylamino)acetamido)-2-methylpropyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- eye lopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)

pentamethyl-3a-(2-((2-methyl-2-(2-morpholinoacetamido)propyl)amino)ethyl)-2-ox 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecariydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(piperidine-4-carboxamido)propyl)amino)ethyl)-2

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l- aminocyclobutyl)methyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid

(lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((3-aminooxetan-3- yl)methyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid, and (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl-5a,5b,8,8,l la- pentamethyl-3a-(2-((2-methyl-2-(6-methylpicolinamido)propyl)amino)ethyl)-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid; or pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

10. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and at least one pharmaceutically acceptable excipient. 11. The pharmaceutical composition according to claim 10, wherein the pharmaceutically acceptable excipient is a carrier or diluent.

12. A method for preventing, ameliorating or treating a viral mediated disease, disorder or syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-5.

13. The method according to claim 12, wherein the viral mediated disease, disorder or syndrome is HIV infection, HBV infection, HCV infection, a retroviral infection genetically related to AIDS, respiratory disorders (including adult respiratory distress syndrome (ARDS)), inflammatory disease, or a combination thereof.

14. A method of treating HIV in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-5. 15. Use of a compound according to any of claim 1-5, in the manufacture of a medicament for the treatment of viral mediated diseases.

16. A pharmaceutical composition comprising a compound according to claim 9 and at least one pharmaceutically acceptable excipient.

17. A method for preventing, ameliorating or treating a viral mediated disease, disorder or syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 9. 18. A method of treating HIV in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 9.

19. The method according to claim 18, wherein the subject is a mammal including human.

20. Use of a compound according to any of claim 9, in the manufacture of a medicament for the treatment of viral mediated diseases.
Description:
C-3 NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORS

This application claims the benefit of Indian provisional application no. 7059/CHE/2015 filed on 30 th December 2015 which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to C-3 novel triterpenone derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

BACKGROUND OF THE INVENTION

The Human Immunodeficiency Virus (HIV) has now been established as the causative agent of the Acquired Immunodeficiency Syndrome (AIDS) for over 20 years (Science 1983, 220, 868-871; N.Eng.J.Med. 1984, 311, 1292-1297). AIDS is characterized by the destruction of the immune system, particularly of CD4+T-cells. HIV is a retrovirus, and the HIV life cycle encompasses several crucial steps, starting from the attachment of the virus to the host cell membrane and finishing with the release of progeny virons from the cell.

The natural compound betulinic acid, isolated from Syzygium clavifolium and several other plant species was found to possess anti-HIV activity. Chemical modifications were undertaken by several research groups in an attempt to identify potent anti-HIV agents by making semi- synthetic analogs of betulinic acid, leading to the discovery of Bevirimat as a compound with a novel mechanism of action (J. Nat. Prod. 1994, 57(2): 243-7; J. Med. Chem. 1996, 39(5), 1016). Further studies shown that Bevirimat acts by disrupting Gag processing (Proc. Natl. Acad. Sci. USA 2003, 100(23): 13555-60; Antimicrob. Agents. Chemother. 2001, 45(4), 1225-30; J. Virol. 2004, 78(2): 922-9; J. Biol. Chem. 2005, 280(51): 42149-55; J. Virol. 2006, 80(12): 5716-22) and to be a first-in-class maturation inhibitor with a potent activity against HIV-1. Bevirimat went up to phase 2 clinical trials, in clinic despite optimal plasma concentrations, not all patients given Bevirimat have a robust viral load reduction. It was reported that non-respondant patients had more frequent base line Gag polymorphisms near the capsid SP-1 cleavage site than responders. (HIV gag polymorphism determines treatment response to bevirimat. XVII international HIV drug resistance work shop June 10-14, 2008, Sitges, Spain).

Encouraged by these developments, medicinal chemists started exploring betulinic acid derivatives and related compounds intensively for their therapeutic activities. For example, WO 2014/105926 disclosed novel betulinic acid proline derivatives as HIV inhibitors; WO 2013/160810 disclosed novel betulinic acid derivatives as HIV inhibitors; WO 2011/007230 describes preparation of lupeol-type triterpene derivatives as antiviral agents; WO 2014/093941 describers pharmaceutical compositions of betulin derivatives; WO 2009/082819 describes preparation of 17-amino lupane derivatives as anti-HIV agents; WO 2013/020245 describes carbonyl derivatives of betulin; WO 2009/082818 describes preparation of C21-keto lupane derivatives for the treatment of HIV Infections; WO 2011/100308 describes preparation of betulin derivatives for treatment of HIV-1; WO 2013/090664 describes preparation of betulin derivatives for the treatment of HIV; WO 2013/117137 describes lupane triterpenoids derivatives and pharmaceutical use thereof; WO 2013/091144 describes preparation of propenoate derivatives of betulin useful for the treatment of HIV.

Some additional references disclose betulinic acid related compounds. For example, WO 2013/090683 describes preparation of betulin propenoate derivatives for the treatment of HIV; WO 2013/020246 describes preparation of methylene derivatives of betulin useful for the treatment of HIV; WO 2010/132334 describes C3, 28-disubstituted betulinic acid derivatives as Anti-HIV agents; US 2011/0152229 describes betulinic acid derivatives as anti-HIV agents; WO 2008/057420 describes extended triterpene derivatives as antiretroviral agents; WO 2013/123019 describes C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity; WO 2007/141392 describes compositions comprising betulonic acid; WO 2007/141391 describes betulin derived compounds useful as antiprotozoal agents; WO 2007/141390 describes the preparation of betulin derived compounds as antiviral agents; WO 2007/141389 describes preparation of betulin derived compounds as antibacterial agents.

Given the fact of the world wide epidemic level of AIDS, there is a strong continued need for new effective drugs for treatment of HIV infected patients, disease conditions and/or disorders mediated by HIV by discovering new compounds with novel structures and/or mechanism of action(s).

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to the compounds of the formula (I):

wherein,

optionally substituted Ci-C 6 alkyl,

or (wherein

R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R 2 at each occurrence are independently selected from hydrogen, alkyl, halo, haloalkyl;

R 3 at each occurrence are independently selected from hydrogen, halo, haloalkyl, alkyl, or -OR t ,; wherein R is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, - C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)cycloalkyl, -C(0)arylalkyl, -

C(0)heterocyclylalkyl, -C(0)cycloalkylalkyl, , or ; alternatively, R 2 and R 3 taken together with the carbon atom to which they are attached form an oxo;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)R c ; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)0- alkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, -NHC(0)alkyl, -N(CH 3 )C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R 6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C 6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R 6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R 6 together represent an oxo; wherein the optional substituents are independently selected from one or more R d ;

W is absent, -NR 8 - -NR 8 (CO)-, -NR 8 (CR 8 R 8a )i_ 3 - or -NR 8 S(0) 2 -; R 7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Q-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C 6 -Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more R e ;

R 8 and R 8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more R d ;

R c is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH 3 ) 2 , -C(0)OH, -C(0)NH 2 , hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

R d is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH 2 , haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl;

'm' is an integer selected from lor 2; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In another aspect, the present invention relates to pharmaceutical composition comprising C-3 novel triterpenone derivatives and related compounds of formula (I) and processes for preparing thereof. In yet another aspect, the present invention relates to C-3 novel triterpenone derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the present invention relates to C-3 novel triterpenone derivatives and related compounds, compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Each embodiment is provided by way of explanation of the invention, and not by way of limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the compounds, compositions, and methods described herein without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be applied to another embodiment to yield a still further embodiment. Thus it is intended that the present invention include such modifications and variations and their equivalents. Other objects, features, and aspects of the present invention are disclosed in, or are obvious from, the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not to be construed as limiting the broader aspects of the present invention.

In certain embodiments, the present invention relates to compounds of formula (I):

wherein,

Ri is optionally substituted Ci-C 6 alkyl,

< s (wherein

R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R 2 at each occurrence are independently selected from hydrogen, alkyl, halo, or haloalkyl;

R 3 at each occurrence are independently selected from hydrogen, halo, haloalkyl, alkyl, or -OR b ,; wherein R b is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, - C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)cycloalkyl, -C(0)arylalkyl, - C(0)heterocyclylalkyl, -C(0)cycloalkylalkyl, or

and R 3 taken together with the carbon atom to which they are attached form an oxo;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)R c ; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)0- alkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, -NHC(0)alkyl, -N(CH 3 )C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R 6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C 6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R 6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R 6 together represent an oxo; wherein the optional substituents are independently selected from one or more R d ;

W is absent, -NR 8 - -NR 8 (CO)-, -NR 8 (CR 8 R 8a )i- - or -NR 8 S(0) 2 -;

R 7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C 6 -Ci 2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more R e ; R 8 and R 8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more R d ;

R c is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH 3 ) 2 , -C(0)OH, -C(0)NH 2 , hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

R d is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH 2 , haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl;

'm' is an integer selected from lor 2; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In certain embodiments, the present invention relates to compounds of formula (IA)

wherein, R is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, -C(0)alkyl, -C(0)aryl optionally substituted with halo, -C(0)arylalkyl, or

R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R 2 and R 3 are independently hydrogen or alkyl;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)R c ; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)0- alkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, -NHC(0)alkyl, -N(CH 3 )C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R 6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C 6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R 6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R 6 together represent an oxo; wherein the optional substituents are independently selected from one or more R d ;

W is absent, -NR 8 - -NR 8 (CO)-, -NR 8 (CR 8 R 8a )i_ 3 - or -NR 8 S(0) 2 -;

R 7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C 6 -Ci 2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4- 15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more R e ;

R 8 and R 8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more R d ;

R c is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH 3 ) 2 , -C(0)OH, -C(0)NH 2 , hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

R d is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH 2 , haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In certain embodiments, the present invention relates to compounds of formula (IB)

wherein, Ri is optionally substituted Ci-C 6 alkyl,

(wherein

R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)R c ; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl) , hydroxy alkylamino , alkoxy alkylamino , alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)0- alkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, -NHC(0)alkyl, -N(CH 3 )C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R 6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C 6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R 6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R 6 together represent an oxo; wherein the optional substituents are independently selected from one or more R d ;

W is absent, -NR 8 - -NR 8 (CO)-, -NR 8 (CR 8 R 8a )i_ 3 - or -NR 8 S(0) 2 -;

R 7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C 6 -Ci 2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more R e ;

R 8 and R 8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more R d ;

R c is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH 3 ) 2 , -C(0)OH, -C(0)NH 2 , hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

R d is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH 2 , haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In certain embo formula (IC)

wherein,

Ri is optionally substituted Ci-C 6 alkyl,

, or R.OOC (wherein

R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C3-C8 cycloalkyl);

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)R c ; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl) , hydroxy alkylamino , alkoxy alkylamino , alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)0- alkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, -NHC(0)alkyl, -N(CH 3 )C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R 6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C 6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R 6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R 6 together represent an oxo; wherein the optional substituents are independently selected from one or more R d ;

W is absent, -NR 8 - -NR 8 (CO)-, -NR 8 (CR 8 R 8a )i_ 3 - or -NR 8 S(0) 2 -;

R 7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C 6 -Ci 2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more R e ;

R 8 and R 8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more R d ; R c is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH 3 ) 2 , -C(0)OH, -C(0)NH 2 , hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

R d is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH 2 , haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In certain embodiments, the present invention relates to compounds of formula (ID)

wherein,

R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C 3 -C 8 cycloalkyl;

R 2 at each occurrence are independently selected from hydrogen, alkyl, halo, or haloalkyl;

R 3 at each occurrence are independently selected from hydrogen, halo, haloalkyl, alkyl, or -OR t ,; wherein R is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, - C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)cycloalkyl, -C(0)arylalkyl, - C(0)heterocyclylalkyl, -C(0)cycloalkylalkyl, I , or o ; alternatively, R 2 and R 3 taken together with the carbon atom to which they are attached form an oxo;

R4 is selected from hydrogen, optionally substituted alkyl, or -C(0)R c ; wherein the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, alkylamino, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)0- alkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, -NHC(0)alkyl, -N(CH 3 )C(0)alkyl, - C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, -C(0)heterocyclyl, -C(0)heterocyclylalkyl, -C(0)aryl, or -C(0)arylalkyl;

R5 and R 6 are independently selected from hydrogen, hydroxy, optionally substituted Ci-C 6 alkyl, halo, haloalkyl, optionally substituted hydroxyalkyl, or optionally substituted aminoalkyl; alternatively R5 and R 6 can be taken together with the carbon atom to which they are attached to form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3- 8 membered heterocyclyl; or R5 and R 6 together represent an oxo; wherein the optional substituents are independently selected from one or more R d ;

W is absent, -NR 8 - -NR 8 (CO)-, -NR 8 (CR 8 R 8a )i_ 3 - or -NR 8 S(0) 2 -;

R 7 is hydrogen, -C(0)OH, amino, optionally substituted aminoacid, optionally substituted Ci-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, -NHC(0)cycloalkyl, optionally substituted C 6 -Ci 2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, or optionally substituted 4-15 membered heteroaryl; wherein the substituents can be independently selected from one or more R e ;

R 8 and R 8a at each occurrence are hydrogen, or selected from the group consisting of optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylalkyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo; wherein the optional substituents at each occurrence are selected from one or more R d ; R c is selected from alkyl, aminoalkyl, dialkylaminoalkyl, alkylaminoalkyl, alkoxyalkyl, -C(0)dialkylaminoalkyl, -C(0)N(CH 3 ) 2 , -C(0)OH, -C(0)NH 2 , hydroxyalkyl, heterocyclyl, aryl, arylalkyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl;

R d is alkyl, amino, halolalkyl, hydroxy, alkoxy or halogen;

R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH 2 , haloalkyl, haloalkyloxy or halo; wherein the optional substituents are alkyl, amino, halo, haloalkyl, hydroxy, alkoxy, aryl, cycloalkyl and heterocyclyl;

'm' is an integer selected from lor 2; and

'n' is an integer selected from 0, 1, 2, 3, 4 or 5; or

pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, prodrugs, or combination thereof.

In accordance with any of the foregoing embodiments, in certain embodiments of

formula (I), (IA), (IB) or (IC); Ri is wherein R a is hydrogen, optionally substituted Ci-C 6 alkyl, or optionally substituted C 3 -C 8 cycloalkyl.

In certain embodiments of formula (I) and (ID), R 2 at each occurrence is selected from hydrogen or alkyl; and R 3 at each occurrence is selected from hydrogen, alkyl, or - ORt,; wherein R is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, -C(0)alkyl, -

C(0)aryl, -C(0)arylalkyl, I , or alternatively, R 2 and R 3 taken together with the carbon atom to which they are attached form an oxo;

In certain embodiments of formula (I), (IA), or (ID); wherein R is hydrogen, or selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, alkoxylalkyl, -C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, (0)cycloalkyl, -C(0)arylalkyl, -C(0)heterocyclylalkyl, -C(0)cycloalkylalkyl, I

In certain embodiments of formula (I), (IA), or (ID); R 2 is hydrogen, and R 3 is -OR b ,; wherein R is hydrogen or alkyl

In certain embodiments of formula (I), (IA), (IB), (IC) and (ID); R 4 is hydrogen or optionally substituted alkyl.

In certain embodiments of the preceding embodiment, the optional substituents are selected from amino, alkylamino, dialkylamino, alkoxy, hydroxy, heterocyclyl, heteroaryl, acyl(alkyl)amino, cycloalkyl, aryl (optionally substituted with halo, or dialkylaminoalkyl), hydroxy alkylamino, alkoxy alkylamino, alkoxyalkylaminoalkyl, -C(0)OH, -C(0)N(H)alkyl, -C(0)N(CH 3 ) 2 , -C(0)NH 2 , -NHC(0)Oalkyl, -N(CH 3 )C(0)Oalkyl, -N(CH 3 )alkoxy, - NHC(0)alkyl, -N(CH 3 )C(0)alkyl, -C(0)N(H)cycloalkyl, -C(0)N(H)cycloalkylalkyl, or - C(0)heterocyclyl,

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); R5 and R 6 independently are hydrogen or alkyl.

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); R5 and R 6 are taken together with the carbon atom to which they are attached represent an oxo.

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); R5 and R 6 are taken together with the carbon atom to which they are attached to form cycloalkyl or heterocyclyl ring.

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); wherein 'n' is absent. In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); wherein 'n' is an integer 1, 2 or 3.

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); wherein W is absent. In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); wherein W is -NR 8 -,

-NR 8 (CO)-, -NR 8 (CR 8 R 8a ) ! _ 3 -, or -NR 8 S(0) 2 -.

In certain embodiments of the preceding embodiment, R 8 and R 8a at each occurrence are hydrogen, or optionally substituted alkyl, or optionally substituted acyl; alternatively R 8 and R 8a are taken together with the carbon atom to which they are attached to form an optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl; or R 8 and R 8a together represent an oxo. In certain embodiments of the preceding embodiment; the optional substituents at each occurrence is selected from one or more R^; wherein R is hydrogen or halogen.

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); R 7 is hydrogen.

In certain embodiments of formula (I), (IA), (IB), (IC) or (ID); R 7 is -C(0)OH, optionally substituted Ci-C 6 alkyl, optionally substituted alkoxy, optionally substituted amine, optionally substituted aminoalkyl, -NHC(0)aryl, -NHC(0)heterocyclyl, NHC(0)cycloalkyl, optionally substituted C 6 -Ci2 aryl, aryloxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted 4-15 membered heterocyclyl, optionally substituted 4-15 membered heteroaryl.

In certain embodiments of the preceding embodiment; the optional substituents at each occurrence is selected from one or more R e ; wherein R e is alkyl, hydroxy, alkoxy, alkoxyalkoxy, amino, acyl, optionally substituted aryl, alkoxycarbonyl, alkylsulfonyl, dialkylaminoalkoxy, optionally substituted 3-8 membered cycloalkyl, optionally substituted heterocyclyl, optionally substituted 3-8 membered cycloalkylalkyl, optionally substituted 3-8 membered arylalkyl, optionally substituted 3-8 membered heterocyclylalkyl, optionally substituted 3-8 membered heterocyclylalkoxy, optionally substituted 3-8 membered heterocyclyloxy, hydroxy, -C(0)OH, oxo, -S(0) 2 NH2, haloalkyl, haloalkyloxy or halo.

In certain embodiments, the compounds of formula (I) can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses. The present invention is meant to include all suitable isotopic variations of the compounds of generic formula I. For example, different isotopic forms of hydrogen (H) include protium ( 1H) and deuterium ( 2 H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may provide certain therapeutic advantages, such as increasing in vivo half -life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.

Isotopically-enriched compounds of formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates. In one embodiment, a compound of formula (I) has one or more of its hydrogen atoms replaced with deuterium.

The representative compounds according to the present invention including the compounds disclosed in the experimental section are illustrative in nature only and are not intended to limit to the scope of the invention. (Nomenclature wherever applicable has been generated from ChemBioDraw Ultra 13.0 version).

In further yet another embodiment, the compounds of formula (I) structurally encompasses all stereoisomers, enantiomers and diastereomers, and pharmaceutically acceptable salts that may be contemplated from the chemical structure of the general formula (I) described herein.

The absolute configuration at an asymmetric atom is specified by either R or S. Resolved compounds whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 5%, in particularly less than 2% or 1 % of the other isomers. Thus when a compound of formula (I) is for instance specified as (R), this means that the compound is substantially free of (S) isomer; when the compound of formula (I) is for instance specified as E, this means that the compound is free of the Z isomer; when the compound of formula (I) is for instance specified as cis isomer, this means that the compound is free of the trans isomer.

In further yet another embodiment, the prodrugs of present invention are the compounds of formula (I) and its pharmaceutically acceptable salts, stereo siomers, solvates thereof containing an hydroxyl group; wherein hydrogen atom of the hydroxyl group are replaced with (Ci-C 6 )alkanoyloxymethyl, l-((Ci-C 6 )alkanoyloxy)ethyl, 1 -methyl- l-((Ci- C 6 )alkanoyloxy)ethyl, (Ci-C 6 )alkoxycarbonyloxymethyl, N-(Ci-C 6 )alkoxycarbonyl aminomethyl, succinoyl, (Ci-C 6 )alkanoyl, a-amino(Ci-C 4 )alkyl, a-amino(Ci-C 4 )alkylene- aryl, arylacyl and a-aminoacyl, where each a -aminoacyl group is independently selected from the naturally occurring L-amino acids, or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

In further yet another embodiment, the prodrugs of present invention are the compounds of formula (I) and its pharmaceutically acceptable salts, stereosiomers, hydrates, solvates thereof containing an amine group; wherein one or more hydrogen atoms of the amine group is replaced with (Ci-C 6 )alkylcarbonyl, (Ci-C 6 )alkoxycarbonyl, aminocarbonyl, (C3-C 6 )cycloalkylcarbonyl, benzylcarbonyl and the like. The present invention also provides a pharmaceutical composition that includes at least one compound as described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Specifically, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. The compound(s) present in the composition may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or may be diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, or other container.

The compounds and pharmaceutical compositions described herein are useful in the treatment of diseases, conditions and/or disorders mediated by viral infections.

The present invention further provides a method of treating a disease, condition and/or disorder mediated by viral infections in a subject in need thereof by administering to the subject one or more compounds described herein in a therapeutically effective amount to treat that infection, specifically in the form of a pharmaceutical composition.

In another aspect, the present invention relates to combinations comprising a compound of the formula (I) and a second therapeutic agent that is an anti-HIV agent, an anti-HCV agent or anti-TB agents.

In another aspect, the present invention relates to pharmaceutical compositions comprising the compound of formula (I) and one or more second anti-HIV agents and their pharmaceutically acceptable salts and stereoisomers thereof.

In another aspect, the present invention relates to combinations comprising a compound of the formula (I) and one or more second anti-HIV agents selected from the group consisting of Protease inhibitors, Integrase inhibitors, Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion/Entry inhibitors, Pharmacokinetic enhancers, and combinations thereof.

The present invention relates to methods of treatment of HIV infection, AIDS, and AIDS-related conditions by administering to a subject a compound of formula (I) and one or more second therapeutic agents selected from the group consisting of Protease inhibitors, Integrase inhibitors, Nucleoside Reverse Transcriptase inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion/Entry inhibitors, Pharmacokinetic enhancers, and combinations thereof.

In another aspect, the present invention relates to combinations comprising a compound of the formula (I) and one or more second anti-HIV agents wherein the second anti-HIV agent is Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Zidovudine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Nelfinavir, Ritonavir, Cobicistat, Saquinavir, Tipranavir, Enfuvirtide, Maraviroc, Fosetemsavir, Dolutegravir, Elvitegravir, Raltegravir, Bictegravir, Cobetagravir or a combination thereof.

In another aspect of the present invention provides a method for preventing; ameliorating or treating a HIV mediated disease, disorder or syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of the invention. The invention further provides a method, wherein the HIV mediated disease, disorder or syndrome is like AIDS, AIDS related complex, or a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss, or a retroviral infection genetically related to AIDS.

Anti HIV inhibitory potential of the compounds of present invention may be demonstrated by any one or more methodologies known in the art, such as by using the assays described in Mossman T, December 1983, Journal of immunological methods, 65 il2), 55-63 and SPC Cole, cancer chemotherapy and Pharmacology, 1986, 17, 259-263.

The following definitions apply to the terms as used herein:

The term "alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl).

The term "amino acid" refers to a straight or branched hydrocarbon chain containing an amine group, a carboxylic acid group, and a side-chain that is specific to each amino acid and which is attached through the nitrogen atom of the amine group to the rest of the molecule by a single bond, e.g., alanine, valine, isoleucine, leucine, phenylalanine, or tyrosine.

The term "alkylamino" refers to alkyl group as defined above attached via amino linkage to the rest of the molecule. Representative examples of those groups are -NH 2 , - NHCH 3 , -N(CH 3 ) 2 and the like.

The term "aminoalkyl" refers to any amino derivative of an alkyl radical more specifically dimethylamino ethyl and dimethylamino methyl.

The term "aryl" refers to an aromatic radical having from 6 to 14 carbon atoms such as phenyl, naphthyl, tetrahydronapthyl, indanyl, and biphenyl. The term "alkoxy" refers to a straight or branched hydrocarbon chain with oxygen radical consisting carbon and hydrogen atoms, containing saturation or unsaturation, having from one to eight carbon atoms, and which is attached through oxygen atom to the rest of the molecule by a single bond, e.g., methyloxy, ethyloxy, n-propyloxy, 1-methylethyloxy (isopropyloxy), n-butyloxy, n-pentyloxy, and 1,1-dimethylethyloxy (t-butyloxy).

The term "amine" refers to an organic compounds and functional groups that contain a basic nitrogen atom with a lone pair. Amines are derivatives of ammonia, wherein one or more hydrogen atoms have been replaced by a substituent such as an alkyl or aryl group these may respectively be called alkylamines and arylamines; amines in which both types of substituent are attached to one nitrogen atom may be called alkylarylamines. Important amines include amino acids, trimethylamine, and aniline.

The term "aminoalkyl" refers to any amino derivative of an alkyl radical specifically methylamino.

The term "alkylaminoalkyl" refers aminoalkyl radicals having the nitrogen atom substituted with an alkyl radical.

The term, "dialkylamino" refers -N(alkyl)alkyl; wherein alkyl is as defined above. The term, "dialkylaminoalkyl" refers to alkylamino groups attached to an alkyl group. Examples include, but are not limited to, Ν,Ν-dimethylaminomethyl, N,N- dimethylaminoethyl Ν,Ν-dimethylaminopropyl, and the like.

The term hydroxyalkylamino group denotes an (HO-alkyl) 2 -N- group or HO-alkyl-

NH- group, the alkyl group being as defined above.

The term "acyl" refers to a group R-CO- wherein R is an optionally substituted alkyl group defined above. Examples of 'acyl' groups are, but not limited to, CH 3 CO-, CH 3 CH 2 CO- , CH 3 CH 2 CH 2 CO- or (CH 3 ) 2 CHCO-.

The term "acyl(alkyl)amino" means -N(Ci-C 6 alkyl)acyl; wherein alkyl and acyl are as defined above.

The term "alkoxyalkyl" refers to the alkyl group as defined above, which is attached to the alkoxy group as defined above.

The term "alkoxycarbonyl" means an alkoxy-C(O)- group, in which the alkyl group as defined above.

The term "alkoxy alkylamino" means alkoxyalkyl group attached to an amino group wherein the alkoxyalkyl and amino are defined as above. The term "alkoxyalkylaminoalkyl" means alkoxyalkyl group attached to an aminoalkyl group wherein the alkoxyalkyl and aminoalkyl are defined as above.

The term "aryloxy" refers to an aryl group as defined above attached via an oxygen linkage to the rest of the molecule. Examples of aryloxy moiety include, but are not limited to phenoxy and naphthoxy. Unless set forth or recited to the contrary, all aryloxy groups described herein may be substituted or unsubstituted.

The term "cycloalkyl" denotes a non-aromatic mono or multicyclic ring system of from 3 to about 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups and spirobicyclic groups, e.g., spiro (4,4) non-2-yl.

The term "cycloalkylalkyl" alone or in combination with other term(s) means alkyl substituted with cycloalkyl group, wherein the terms "alkyl" and "cycloalkyl" are as defined above.

The term "alkylsulfonyl" means a -S0 2 R radical where 'R' is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.

The term "halogen" or "halo" includes fluorine, chlorine, bromine, or iodine.

The term "haloalkyl" refers to alkyl group (as defined above) is substituted with one or more halogens. A monohaloalkyl radical, for example, may have a chlorine, bromine, iodine or fluorine atom. Dihalo and polyhaloalkyl radicals may have two or more of the same or different halogen atoms. Examples of haloalkyl include, but are not limited to, chloromethyl, dichloromethyl, trichloromethyl, dichloroethyl, dichloropropyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, difluoro chloromethyl, dichloro fluoromethyl, difluoroethyl, difluoropropyl and the like.

The term "hydroxy" means -OH.

The term "haloalkoxy" or "haloalkyloxy" refers the radical -O-haloalkyl, wherein the haloalkyl is as defined above. Representative examples of haloalkoxy include, but are not limited to, fluoromethoxy, trifluoromethoxy and 2-fluoroethoxy.

The term "hydroxyalkyl" or "hydroxylalkyl" means alkyl substituted with one or more hydroxyl groups, wherein the alkyl groups are as defined above. Examples of "hydroxyalkyl" include but are not limited to hydroxymethyl, hydroxyethyl, hydroxypropyl, propan-2-ol and the like.

The terms "heterocyclyl" and "heterocyclic ring" refer to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heterocyclic or heteroaryl). Examples of such heterocyclic ring radicals include, but are not limited to, tetrazoyl, tetrahydroisouinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxasolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzothiazolyl, benzooxazolyl, furyl, tetrahydrofurnyl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, oxadiazolyl, imidazolyl, pyridinyl, (lR,5S)-8-oxabicyclo[3.2.1]octane, 8-oxabicyclo[3.2.1]octane, tetrahydropyranyl, azitidine, oxitane. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.

The term "heteroaryl" refers to an aromatic heterocyclic ring radical. Examples of such heteroaryl include, but are not limited to pyridyl, pyrazinyl, furanyl, quinolinyl, tetrazoyl , triazolyl, 1,3-Diaza-lH-indenyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, pyrazolo[l,5-a]pyrimidinyl, 1,3,4-Oxadiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl and isoindolinyl. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.

The term "arylalkyl" or "heterocyclylalkyl" refers to an alkyl group which is further substituted by aryl or heterocyclyl respectively, wherein aryl, heterocyclyl and alkyl are as above defined.

The term "oxo" refers to -C(O)-

The term "Heterocyclyloxy" refers to the group -O-heterocyclyl. wherein the heterocyclyl groups are as defined above.

The term "heterocyclylalkoxy" as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through an alkoxy group. Wherein heterocyclyl and alkoxy groups are same as defined above. "Substituted" refers to 1-3 substituents on the same position or on different positions with the same groups or different groups. Unless otherwise specified, the term "substituted" as used herein refers to substitution with any one or any combination of the following substituents: hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, and substituted or unsubstituted guanidine.

The term "prodrug" denotes a derivative of a compound, which derivative, when administered to warm -blooded animals, e.g. humans, is converted into the compound (drug). The enzymatic and/or chemical hydrolytic cleavage of the compounds of the present invention occurs in such a manner that the proven drug form (parent carboxylic acid drug) is released, and the moiety or moieties split off remain nontoxic or are metabolized so that nontoxic metabolic products are produced. For example, a carboxylic acid group can be esterified, e.g., with a methyl group or ethyl group to yield an ester. When an ester is administered to a subject, the ester is cleaved, enzymatically or non-enzymatically, reductively, oxidatively, or hydrolytically, to reveal the anionic group. An anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which are cleaved to reveal an intermediate compound which subsequently decomposes to yield the active compound. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

The term "treating" or "treatment" of a state, disease, disorder or condition includes:

(1) preventing or delaying the appearance of clinical symptoms of the state, disease, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disease, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disease, disorder or condition; (2) inhibiting the state, disease, disorder or condition, i.e., arresting or reducing the development of the state, disease, disorder or condition or at least one clinical or subclinical symptom thereof; or

(3) relieving the state, disease, disorder or condition, i.e., causing regression of the state, disease, disorder or condition or at least one of its clinical or subclinical symptoms.

The benefit to a subject receiving treatment is either statistically significant or at least perceptible to the subject or to the physician.

The term "subject" includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).

A "therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a state, disease, disorder or condition, is sufficient to effect such treatment. The "therapeutically effective amount" will vary depending on the compound, the state, disease, disorder or condition and its severity and the age, weight, physical condition and responsiveness of the subject receiving treatment.

The compounds of the present invention may form salts. Non-limiting examples of pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases salts of organic bases salts of chiral bases, salts of natural amino acids and salts of non-natural amino acids. Certain compounds of the present invention are capable of existing in stereo isomeric forms (e.g., diastereomers, enantiomers, racemates, and combinations thereof). With respect to the overall compounds described by the Formula (I), the present invention extends to these stereo isomeric forms and to mixtures thereof. To the extent prior art teaches synthesis or separation of particular stereoisomers, the different stereo isomeric forms of the present invention may be separated from one another by the methods known in the art, or a given isomer may be obtained by stereo specific or asymmetric synthesis. Tautomeric forms and mixtures of compounds described herein are also contemplated.

Pharmaceutically acceptable solvates includes hydrates and other solvents of crystallization (such as alcohols). The compounds of the present invention may form solvates with low molecular weight solvents by methods known in the art.

PHARMACEUTICAL COMPOSITIONS

The pharmaceutical compositions provided in the present invention include at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Specifically, the contemplated pharmaceutical compositions include a compound(s) described herein in an amount sufficient to treat viral infection in a subject.

The subjects contemplated include, for example, a living cell and a mammal, including human. The compound of the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, or other container.

Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters, and polyoxyethylene.

The carrier or diluent may include a sustained release material, such as, for example, glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, emulsifying agents, suspending agents, preserving agents, salts for influencing osmotic pressure, buffers, sweetening agents, flavoring agents, colorants, or any combination of the foregoing. The pharmaceutical composition of the invention may be formulated so as to provide quick-, sustained-, or delayed-release of the active ingredient after administration to the subject by employing procedures known in the art.

The pharmaceutical compositions described herein may be prepared, e.g., as described in Remington: The Science and Practice of Pharmacy, 20 th Ed., 2003 (Lippincott Williams & Wilkins). For example, the active compound can be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampule, capsule, or sachet. When the carrier serves as a diluent, it may be a solid, semi- solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound.

The pharmaceutical compositions may be in conventional forms, for example, capsules, tablets, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present invention may be formulated so as to provide desired release profile.

The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal, parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic (such as with an ophthalmic solution) or topical (such as with a topical ointment). The oral route is specifically suitable.

Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Exemplary carriers for tablets, dragees, or capsules include lactose, cornstarch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

A typical tablet that may be prepared by conventional tableting techniques.

Liquid formulations include, but are not limited to, syrups, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions.

For parenteral application, particularly suitable are injectable solutions or suspensions, specifically aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

METHODS OF TREATMENT

The present invention provides compounds and pharmaceutical formulations thereof that are useful in the treatment of diseases, conditions and/or disorders mediated by viral infections. The connection between therapeutic effect and antiviral is illustrated. For example, PCT publication Nos. WO 01//07646, WO 01/65957, or WO 03/037908; US publication Nos. US 4,598,095 or US 2002/0068757; EP publication Nos. EP 0989862 or EP 0724650; Bioorganic & Medicinal Chemistry Letters, 16, (6), 1712-1715, 2006; and references cited therein, all of which are incorporated herein by reference in their entirety and for the purpose stated.

The present invention further provides a method of treating a disease, condition and/or disorder mediated by viral infections in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention.

Diseases, conditions, and/or disorders that are mediated by viral infections are believed to include, but are not limited to, ΗΓ infection, HBV, HCV, a retroviral infection genetically related to HIV, AIDS, inflammatory disease, respiratory disorders (including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis and chronic sinusitis), inflammatory bowel disease (including Crohn's disease and ulcerative colitis), multiple sclerosis, rheumatoid arthritis, graft rejection (in particular but not limited to kidney and lung allografts), endometriosis, type I diabetes, renal diseases, chronic pancreatitis, inflammatory lung conditions, chronic heart failure and bacterial infections (in particular but not limited to tuberculosis).

The compounds of the present invention can obtain more advantageous effects than additive effects in the prevention or treatment of the above diseases when using suitably in combination with the available drugs. Also, the administration dose can be decreased in comparison with administration of either drug alone, or adverse effects of co administrated drugs other than antiviral can be avoided or declined.

PHARMACOLOGICAL ACTIVITY

The compounds described herein can be tested for their antiviral activity following procedures known to a person of ordinary skill in the art. For example, the following protocols can be employed for testing the compounds. These protocols are illustrative and do not limit to the scope of the invention.

Example : Evaluation of compounds antiviral activity:

MT2 cells were infected with HIV-1 strain 92HT599 (10 TCID 50/ 30000 cells). The infected cells were plated at the concentration of -30,000 cells per well in 96 well plate. Test compound was added to the micro plate in defined format with the final concentration of DMSO (vehicle) is not more than 1%. Incubation was carried out in C0 2 incubator for - 96 hours for viral infection. At the end of incubation period an aliquot from each well was taken for p24 estimation. The quantitation of p24 is an index for antiviral activity of the compound. Percentage inhibition was calculated with reference to control values (vehicle controls).

P-24 estimation was carried out using Advance biosciences kit as per the procedure detailed by supplier.

Results:

Compounds of the present invention were tested for anti-viral activity and exhibited IC 50 values less than 1 μΜ using the assay disclosed herein.

METHODS OF PREPARATION

The compounds described herein may be prepared by techniques known in the art. In addition, the compounds described herein may be prepared by following the reaction sequence as depicted in below schemes. Further, in the following schemes, where specific bases, acids, reagents, solvents, coupling agents, etc., are mentioned, it is understood that other bases, acids, reagents, solvents, coupling agents etc., known in the art may also be used and are therefore included within the present invention. Variations in reaction conditions, for example, temperature and/or duration of the reaction, which may be used as known in the art, are also within the scope of the present invention. All the stereoisomers of the compounds in these schemes, unless otherwise specified, are also encompassed within the scope of this invention.

Abbreviations: The abbreviations used in the entire specification may be summarized herein below with their particular meaning: 1H NMR (Proton Nuclear Magnetic Resonance); Hz (hertz); MHz (megahertz); CDCI 3 (Deuterated chloroform); DMSO-d 6 (Deuterated Dimethylsulfoxide); CD 3 OD (Deuterated methanol); DMSO (Dimethylsulfoxide); δ (delta); ppm (parts per million); s (singlet); d (doublet); dd (doublet of doublets); m (multiplet); q (quartet); J (coupling constant); JAB (coupling constant); ml or mL (milliliter); °C (degree celsius); mol (mole(s)); mmol (millimole(s)); M (molar); N (Normal); mg (milligram(s)); g (gram(s)); mm (millimeter(s)); Ac 2 0 (acetic anhydride); DIPEA (N,N- Diisopropylethylamine); % (percentage); EtOH (ethanol); EtOAc (Ethyl acetate); H or H 2 (hydrogen); HC1 (Hydrochloric acid); h or hr (hours); HATU (0-(7-Azabenzotriazol-l-yl)- Ν,Ν,Ν',Ν'-tetramethyluroniumhexafluorophosphate); HPLC (High-performance liquid chromatography); ESI-MS (Electrospray ionization mass spectrometry); m/z (mass-to-charge ratio); M+H + (parent mass spectrum peak plus H + ); M+Na + (parent mass spectrum peak plus sodium "1" ); min (Minutes); mM (millimolar); NaOH (Sodium hydroxide); N 2 (Nitrogen); TEA (triethylamine); TLC (Thin Layer Chromatography); THF (Tetrahydrofuran); CH 3 CN (acetonitrile); H 2 0 (water); tert (tertiary), TFA/CF 3 COOH (Trifluoro acetic acid); t (triplet); IC (Inhibitory concentration), nM (Nano molar); pH (Pouvoir hydrogen); (Boc) 2 0 (di-tert- butyl dicarbonate); DCM or CH 2 C1 2 (dichloromethane); KI (Potassium iodide), DMF (N,N- dimethylformamide); DMAP (4-(Dimethylamino)pyridine); eq (equivalent); Ltr or L (Liter(s)); NaH 2 P0 4 (Sodium dihydrogen phosphate); Na(OAc) 3 BH (Sodium triacetoxyborohydride); AcOH (Acetic acid); NaB¾CN (Sodium cyanoborohydride); ABq (AB quartet); MTBE (Methyl tert-butyl ether); HBr (Hydrogen bromide); NaHC0 3 (Sodium bicarbonate); Na 2 S0 4 (Sodium sulfate); 1,2-DCE (1,2-dichloroethane); HBTU (O- (Benzotriazol-l-yl)-N,N,N',N'-tetramethyluroniurnhexafluorop hosphate); KOH (Potassium hydroxide); MeOH (methanol); EDCI (l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide); HOBt (1-Hydroxybenzotriazole); br.s. (broad singlet); ZrCl 4 (zirconium tetrachloride); pTSA (para-toluenesulfonic acid monohydrate); NaBH 4 (sodium borohydride); NiCl 2 -6H 2 0 (Nickel(II) chloride hexahydrate), RB flask (round bottom flask); Cu(OAc) (copper(I) acetate). Compounds of the present invention can be synthesized from naturally occurring Betulin. Key intermediates required for synthesizing analogues are either commercially available or can be prepared by the methods published in the literature. For example, the key intermediates in the present invention were prepared by modifying the procedures published in Journal of organic chemistry 2010, 75, 1285-1288; Journal of organic chemistry 2000, 65, 3934-3940; Tetrahedron: asymmetry 2008, 19, 302-308; or Tetrahedron: asymmetry 2003, 14, 217-223.

Another embodiment of the present invention provides process for preparation of the compounds of general formula (I) are set forth in the below generalized schemes. One of skill in the art will recognize that below generalised schemes can be adapted to produce the compounds of general formula (I) and pharmaceutically acceptable salts of compounds of general formula (I) according to the present invention. Wherein all symbols/variables are as defined earlier unless otherwise stated.

General Synthetic Procedure-A: Scheme-1:

Scheme-1

The compounds of formula (I) (wherein, Ri and R5 are same as defined above) can be prepared as described in scheme-I (Pi and P 2 are protecting groups such as acetyl and benzyl or the like; R m and R n are independently selected from H and substituted or unsubstituted alkyl or the like). The C-3 & C-28 di hydroxy groups in compounds of formula (1) can be protected in different ways like (a) With a suitable ester forming reagent such as anhydride with or without addition of a base or a catalyst under heating conditions or (b) with a suitable ester forming reagents such as anhydrides or acid halides or mixed anhydrides in the presence of a base such as triethylamine (TEA) or N,N-diisopropylethylamine (DIPEA) or pyridine or the like in a solvent such as dichloromethane (DCM) or tetrahydrofuran (THF) or toluene or the like with or without addition of a catalyst such as 4-(Dimethylamino)pyridine (DMAP) under heating conditions to give C-3 & C-28 di hydroxy protected compounds of formula (2).

The compounds of formula (3) can be prepared by the reaction of compounds of formula (2) with hydrogen bromide (HBr) in acetic acid (AcOH), acetic acid (AcOH) and acetic anhydride (Ac 2 0) in a suitable solvent such as toluene or benzene. The compounds of formula (3) can be converted to the compounds of formula (4) with reagents such as sodium dichromate dihydrate (Na 2 Cr 2 0 7 .2H 2 0), sodium acetate (NaOAc), acetic acid (AcOH) and acetic anhydride (Ac 2 0) in a suitable solvent such as toluene or benzene. The C-28 protecting group in compound (4) can be selectively deprotected to the C-28 hydroxy compounds of formula (5) in the presence of a base such as potassium hydroxide (KOH) in the combination of solvents such as toluene: ethanol (EtOH) (1 :1) or with a reagent like Aluminium isopropoxide [Al(OCH(CH 3 ) 2 ) 3 ] in a solvent such as 2-propanol or the like. The C-28 hydroxy compounds of formula (5) can be converted to the C-28 aldehyde compounds of formula (6) in the presence of an oxidizing agent such as pyridinium chlorochromate (PCC) or pyridinium dichromate (PDC) or Dess-Martin periodinane (DMP) or Swern oxidation conditions in a solvent such as dichloromethane (DCM) or the like. The C-3 protecting group in compound (6) can be deprotected to the C-3 hydroxy compound (7) with a reagent like zirconium tetrachloride (ZrCl 4 ) in the combination of solvents such as methanol (MeOH) and dichloromethane (DCM) or the like.

The C-3 esters of compounds of formula (9) can be prepared by the reaction of compound (7) with acids of compounds of formula (8) in different ways like

a) compounds (7) and (8) coupling with a reagent like 2,4,6-trichlorobenzoyl chloride in the presence of a base such as triethylamine (TEA) or N,N-Diisopropylethylamine (DIPEA) or the like and a catalyst such as 4-(Dimethylamino)pyridine (DMAP) in a solvent such as dichloromethane (DCM) or Tetrahydrofuran (THF) or the like, b) compounds (7) and (8) coupling in the presence of a coupling reagent such as 1-ethyl- 3-(3-dimethylaminopropyl)carbodiimide (EDCI) and a catalyst such as 4-

(Dimethylamino)pyridine (DMAP) in an appropriate solvent such as dichloromethane (DCM) or N,N-dimethylformamide (DMF) or the like.

The compounds of formula (9) can be converted to the C-28 hydroxy compounds of formula (10) in the presence of chiral ligand N,N'-bis(isobornyl)ethylenediamine, derived from (S)-camphor reagent like nitromethane, base like Ν,Ν-diisopropylethylamine and a catalyst such as copper(I) acetate [Cu(OAc)] in the combination of solvents such as toluene and ie/ -butanol (t-BuOH). The primary amines of compounds of formula (11) can be prepared by reducing the nitro group in compounds of formula (10) with a reagent like Nickel(II) chloride hexahydrate (NiCl 2 - 6H 2 0) and a reducing agent such as sodium borohydride (NaBH 4 ) in a suitable solvent such as methanol (MeOH) or the like. The secondary amines of compounds of formula (13) can be prepared by the reductive amination of compounds of formula (11) with aldehydes of compounds of formula (12) in the presence of a reducing agent such as sodium triacetoxyborohydride (STAB) or the like in a solvent such as tetrahydrofuran (THF) or the like. The compounds of formula 15 can be prepared by the reductive amination of compounds (13) and (14) with a reducing agent such as sodium cyanoborohydride (NaCNBH 3 ) or the like in the presence of a base such as triethylamine (TEA) or Ν,Ν-diisopropylethylamine (DIPEA) or the like in a solvent such as methanol (MeOH) or the like. Alternatively, the compounds of formula (16) can be prepared by the alkylation of compound of formula (15) with appropriate alkylhalides, alky esylates, alkyltosylates in presence of suitable bases such as NaH, K 2 C0 3 , or Cs 2 C0 3 and the like. The compounds of formula (I) can be prepared by hydrolysing the ester group in compounds of formula (15) or (16) in the presence of aqueous solution of inorganic bases such as potassium carbonate (K 2 C0 3 ) or sodium hydroxide (NaOH) or potassium hydroxide (KOH) or the like in the combination of solvents such as tetrahydrofuran (THF): methanol (MeOH) or the like.

Scheme-2:

The amides of compounds of formula (18) can be prepared by coupling of compounds (17) and compounds of formula (11) in the presence of coupling reagents such as 0-(7- Azabenzotriazol-l-yl)-N,N,N\N'-tetramethyluroniumhexafluorop hosphate (HATU) or O- (Benzotriazol-l-yl)-N,N,N\N'-tetramethyluroniurnhexafluoroph osphate (HBTU) or 1-Ethyl- 3-(3-dimethylaminopropyl)carbodiimide (EDCI) and 1-Hydroxybenzotriazole (HOBt) in the presence of a base such as triethylamine (TEA) or Ν,Ν-Diisopropylethylamine (DIPEA) in a suitable solvent such as Ν,Ν-dimethylformamide (DMF) or 1,2-dichloroethane (1,2-DCE).

The compounds of formula (I) can be prepared by hydrolysing the ester group in compounds of formula (18) in the presence of aqueous solution of inorganic bases such as sodium hydroxide (NaOH) or potassium hydroxide (KOH) or the like in the combination of solvents such as tetrahydrofuran (THF): methanol (MeOH) or the like.

Scheme-2a:

The protected amines of compounds of formula (18b) can be prepared by the reaction of (Boc) 2 0 in the presence of a base such as triethylamine (TEA) or N,N- Diisopropylethylamine (DIPEA) in a suitable solvent such as DCM (Dichloromethane).

The compounds of formula (18c) can be prepared by acetylation with acetic anhydride in the presence of catalyst such as DMAP, and base such as TEA (triethylamine) in a suitable solvent such as DCM or THF. Upon deprotection of compound 18c in the presence of TFA in DCM or HC1 in 1,4-dioxane results in the formation of compound of formula (18d).

Copuling of compound of formula (18d) with suitable alkyl halides of compound of formula (18e) in the presence of bases such as potassium phosphate or potassium carbonate with reagent KI in the presence of solvents such as acetonitrile or the like under heating conditions.

Illustrative example of General synthetic procedure-A:

Example-I-1: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)- 2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-l-hydroxye thyl)-l-isopropyl-5a,5b,8,8, l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H -cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobu tane-l-carboxylic acid:

Step 1: Synthesis of ((lR,3aS,5aR,5bR,7aR,9S,llaR,llbR,13aR,13bR)-9-acetoxy-5a,5b ,8,8, lla-pentamethyl-l-(prop-l-en-2-yl)icosahydro-3aH-cyclopenta[ a]chrysen-3a-yl)methyl acetate:

A mixture of (lR,3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aR,13bR)-3a-(hydroxymethyl)- 5a,5b,8,8,l la-pentamethyl-l-(prop-l-en-2-yl)icosahydro-lH-cyclopenta[a] chrysen-9-ol (400 g, 0.904 mol, 1.0 eq) and acetic anhydride (3.4 Ltr) were heated at 140 °C for about 3 hours. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was cooled to 0 °C, solid was filtered, washed with water (2 Ltr) and dried under vacuum to obtain the desired product (400 g, yield: 84%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 4.68 (d, 1H), 4.59 (s, 1H), 4.50-4.43 (m, 1H), 4.25 (d, = 11.1 Hz, 1H), 3.85 (d, = 11.1 Hz, 1H), 2.50-2.40 (m, 1H), 2.07 (s, 3H), 2.04 (s, 3H), 2.01- 1.71 (m, 4H), 1.70-1.62 (m, 4H), 1.68 (s, 3H), 1.61-1.43 (m, 4H), 1.43-1.36 (m, 4H), 1.33- 1.18 (m, 3H), 1.18-1.09 (m, 1H), 1.08-0.94 (m, 3H), 1.03 (s, 3H), 0.97 (s, 3H), 0.88-0.75 (m, 10H).

Step 2: Synthesis of ((3aS,5aR,5bR,7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl-5 a,5b,8, 8,lla-pentamethyl-2,3,4,5,5a,5b,6, 7,7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-3aH- cyclopenta[a]chrysen-3a-yl)methyl acetate:

HBr in acetic acid (800 ml, 33%), was added to a suspension of {{\R, &S,5aR,5bR, 7a ?,95,l la ?,l lb ?,13a ?,13b ?)-9-acetoxy-5a,5b,8,8,l la-pentamethyl-l-(prop-l-en-2-yl) icosahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate (step 1, 400 g, 0.76 mol, 1.0 eq) in toluene (800 ml), Ac 2 0 (800 ml) and acetic acid (800 ml) previously heated at 105 °C. The reaction mixture was stirred and heated at this temperature for about 1.5 hours. After cooling down, sodium acetate (480 g) was added and the resulting reaction mixture was evaporated to dryness. The residue was taken up in CH 2 C1 2 (1200 ml) and the organic phase was washed with water (2x500 ml), dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue was recrystallized over 95% ethanol and CH 2 C1 2 to obtain the desired product (256 g, yield: 64%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 4.52-4.45 (m, 1H), 4.03 (d, J = 10.8 Hz, 1H), 3.98 (d, J = 10.8 Hz, 1H), 3.19-3.08 (m, 1H), 2.46-2.38 (m, 1H), 2.28-2.22 (m, 2H), 2.05 (s, 3H), 2.04 (s, 3H), 2.01-1.83 (m, 2H), 1.78-1.63 (m, 6H), 1.57-1.44 (m, 3H), 1.43-1.08 (m, 8H), 1.06 (s, 3H), 1.02-0.88 (m, 12H), 0.84 (s, 3H), 0.83 (s, 3H) and 0.78 (m, 1H).

Step 3: Synthesis of ((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl-5a,5b,8, 8,lla-pentamethyl-2-oxo-2,3,4,5,5a,5b,6, 7,7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro- 3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate:

To a stirred solution of ((3a5,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octa decahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate (step 2, 100 g, 0.190 mol, 1.0 eq) in Toluene (1280 ml) was added sodium acetate (88.96 g, 1.08 mol, 5.7 eq), sodium dichromate dihydrate (67.9 g, 0.228 mol, 1.2 eq), Ac 2 0 (414 ml) and AcOH (1700 ml) and heated at 60 °C for about 14 hours. TLC indicated starting material was consumed and the desired product was observed. After cooling down, the reaction mixture was diluted with water (500 ml) and extracted with ethyl acetate (1000 ml). The organic phase was washed successively with saturated solution of sodium carbonate (1x500 ml) and brine (2x200 ml) solution. The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure. The residue was triturated with methanol and the precipitates that formed were collected by filtration were dried under vacuum to obtain the desired product (81 g, yield: 79%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 4.47 (dd, = 10.2, 6.0 Hz, 1H), 4.31 (d, = 10.8 Hz, 1H), 4.03 (d, = 10.8 Hz, 1H), 3.22-3.12 (m, 1H), 2.85 (dd, = 12.3, 3.3 Hz, 1H), 2.36 (d, = 18.6 Hz, 1H), 2.03 (s, 3H), 1.97 (s, 3H), 1.93-1.88 (m, 2H), 1.88-1.62 (m, 6H), 1.61-1.28 (m, 8H), 1.27-1.22 (m, 1H), 1.21-1.12 (m, 9H), 1.09-0.97 (m, 1H), 0.91 (s, 3H), 0.90 (s, 3H), 0.83 (s, 3H), 0.82 (s, 3H) and 0.77-0.75 (m, 1H); ESI-MS: m/z 563.4 (M+Na) + .

Step 4: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(hydroxymethyl)-l-iso propyl -5 a, 5b, 8, 8, 1 la-pentamethyl-2-oxo-3,3a,4, 5, 5 a, 5b, 6, 7,7a,8,9,10,ll,lla,llb,12,13,l 3 a -octa decahydro-2H-cyclopenta[a ]chrysen-9-yl acetate:

To a stirred solution of ((3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a -octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)methyl acetate (step 3, 70 g, 0.129 mol, 1.0 eq) in ethanol (2 L) : toluene (2 L) was added potassium hydroxide (8.72 g, 0.155 mol, 1.2 eq) and stirred at room temperature for about 2 hours. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was neutralized with aqueous IN HQ and evaporated to dryness. The obtained residue was taken up in water (200 ml) and a small amount of acetone (20 ml). The precipitates formed were collected by filtration, washed with water and dried in vacuo to obtain the desired product (51 g, yield: 79%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 4.49 (dd, = 10.5, 6.0 Hz, 1H), 3.73 (d, = 10.5 Hz, 1H), 3.67 (d, = 10.5 Hz, 1H), 3.25-3.14 (m, 1H), 2.78 (dd, = 12.3, 3.0 Hz, 1H), 2.43 (d, = 18.6 Hz, 1H), 2.05 (s, 3H), 2.02-1.65 (m, 8H), 1.60-1.25 (m, 8H), 1.24-1.17 (m, 7H), 1.13 (s, 3H), 1.12-0.97 (m, 1H), 0.94 (s, 3H), 0.92 (s, 3H), 0.86 (s, 3H), 0.85 (s, 3H), 0.80 (m, 1H); ESI-MS: m/z 521.3 (M+Na) + .

Step 5: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-formyl-l-isopropyl-5a ,5b,8, 8,lla-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6, 7,7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro- 2H-cyclopenta[a ]chrysen-9-yl acetate:

To a solution of (3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-(hydroxymethyl)-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9, 10,11,1 la,l lb, 12,13, 13a-octadecahydro -2H-cyclopenta[a]chrysen-9-yl acetate (step 4, 52.0 g, 0.104 mol, 1.0 eq) in CH 2 CI 2 (2 L) at room temperature was added pyridiniumchlorochromate (67.5 g, 0.313 mol, 3.0 eq) and silicagel (100-200 mesh) (67.5 g). The reaction mixture was stirred at room temperature for about 1 hour. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (50 ml) and extracted with CH 2 CI 2. The combined organic layers were washed with saturated sodium bicarbonate solution, dried over sodium sulphate and evaporated under reduced pressure to give a crude product, which was triturated with ethanol, solid was filtered and dried under vacuum to obtain the desired product (41.4 g, yield: 80%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 9.31 (s, 1H), 4.52-4.44 (m, 1H), 3.32-3.18 (m, 1H), 2.60-2.50 (m, 1H), 2.43-2.33 (m, 2H), 2.12-2.0 (m, 2H), 2.05 (s, 3H), 2.0-1.80 (m, 2H), 1.80-1.65 (m, 3H), 1.53-1.18 (m, 15H), 1.12-1.0 (m, 2H), 1.03 (s, 3H), 0.98-0.75 (m, 12H).

Step 6: Synthesis of (3aR,5aR,5bR, 7aR,9S,l laR,l lbR,l 3aS)-9-hydroxy-l -isopropyl-5a,5b,8,

8,lla-pentamethyl-2-oxo-2,3,4,5,5a,5b,6, 7,7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-

3aH-cyclopenta[a]chrysene-3a-carbaldehyde:

To a stirred solution of (3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-formyl-l-isopropyl -5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octa decahydro-2H-cyclopenta[(3]chrysen-9-yl acetate (step 5, 20.0 g, 40.32 mmol, 1.0 eq) in methanol (200 ml) and CH 2 C1 2 (80 ml) was added ZrCl 4 (11.27 g, 48.38 mmol, 1.2 eq) in portions. The reaction was warmed to approximately 45-55 °C and maintained for about 14 hours. The reaction was then treated with water (6 ml) and heated at 45 °C for about 30 minutes. The reaction was then cooled to room temperature and evaporated under vacuum at 40 °C to 60 ml. Dichloromethane (200 ml) was added and the reaction was treated with IN HC1 (100 ml), mixed thoroughly, organic layer was separated and evaporated to 40 ml. Acetonitrile (160 ml) was added and heated at 60 °C, thus forming a clear solution. Then slowly added, 3N HC1 (5 ml), which resulted in precipitate formation, the reaction mixture was heated at 60 °C until dimethyl acetal hydrolysis was complete followed by the addition of water (240 ml). The reaction was allowed to cool to 10 °C, mixture was filtered and the resultant solid was washed with CH 3 CN/H 2 0 (1: 1, 40 ml). The solid was taken in 200 ml of heptane and refluxed at 85-100 °C for about 2 hours. The mixture was then cooled to room temperature, filtered, washed the filter cake with heptane (50 ml) and then dried under vacuum at 40 °C to obtain the desired product (14.0 g, yield: 76.5%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 9.32 (d, = 1.2 Hz, 1H), 3.30-3.18 (m, 2H), 2.56 (dd, = 12.6, 3.0 Hz, 1H), 2.42-2.34 (m, 2H), 2.08-2.02 (m, 2H), 1.97-1.06 (m, 21H), 1.03 (s, 3H), 0.98 (s, 3H), 0.95 (s, 3H), 0.88 (s, 3H), 0.77 (s, 3H), 0.73-0.67 (m, 1H). Step 7: Synthesis of 1-benzyl 3-((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-formyl-l-iso propyl-5a,5b,8,8,lla-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3- dicarboxylate:

To a stirred solution of (3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-9-hydroxy-l-iso propyl-5a,5b,8,8,l la-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-3aH-cyclopenta[a]chrysene-3a-carbaldehyde (step 6, 5.0 g, 11.01 mmol, 1.0 eq) and (15,3 ?)-3-((benzyloxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxy lic acid (prepared as described in WO 2011/007230 A2, 3.45 g, 13.20 mmol, 1.2 eq) in CH 2 C1 2 (100 ml) at 0 °C were added triethylamine (3 ml, 22.0 mmol, 2.0 eq), DMAP (0.67 g, 5.50 mmol, 0.5 eq) and 2,4,6-trichlorobenzoyl chloride (2.14 ml, 13.20 mmol, 1.2 eq). The reaction mixture was allowed to stir at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (300 ml) and extracted with CH 2 C1 2 (2x300 ml). The combined organic extracts were dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-1% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the desired product (7.0 g, yield: 91%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 9.31 (d, 1H), 7.37-7.34 (m, 5H), 5.15, 5.10 (ABq, JAB = 12.3 Hz, 2H), 4.45 (dd, = 11.4, 4.8 Hz, 1H), 3.31-3.20 (m, 1H), 2.86-2.73 (m, 2H), 2.70-2.61 (m, 1H), 2.59-2.51 (m, 1H), 2.42-2.33 (m, 2H), 2.10-1.98 (m, 3H), 1.97-1.08 (m, 21H), 1.34 (s, 3H), 1.03 (s, 3H), 0.97 (s, 3H), 0.94 (s, 3H), 0.90 (s, 3H), 0.85 (s, 3H), 0.84 (s, 3H), 0.82-0.77 (m, 1H); ESI-MS: m/z 721.5 (M+Na) + .

Step 8: Synthesis of 1-benzyl 3-((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-((R)-l-hydroxy- 2-nitroethyl)-l-isopropyl-5a,5b,8, 8,1 la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6, 7,7a,8,9, 10,11, lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl )(lR,3S)-2,2-dimethylcyclo butane -1,3 -dicarboxy late:

To a stirred solution of 1-benzyl 3-((3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-formyl -l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12, 13,13a-octadecahydro-2H-cyclopenta[(3]chrysen-9-yl) (1 ?,35)-2,2-dimethylcyclobutane-l,3- dicarboxylate (step 7, 6.0 g, 8.59 mmol, 1.0 eq) in ie/t-butanol (80 ml) and toluene (30 ml) at 25 °C was added the ligand N,N'-bis(isobornyl)ethylenediamine, derived from (S)-camphor (prepared according to WO 2013/090664 Al, 0.340 g, 1.03 mmol, 0.12 eq) and copper (I) acetate (0.104 g, 0.859 mmol, 0.1 eq) in a single portion and the reaction mixture was then stirred at 20-25 °C for about 4 hours. The reaction was next allowed to cool to 7-13 °C, then charged nitro methane (28.8 g, 472.5 mmol, 55 eq) and N,N-diisopropylethylamine (4.5 ml, 25.7 mmol, 3.0 eq) and allowed to stir at 7-13°C for approximately 4 days. TLC indicated starting material was consumed and the desired product was observed.

Next, the reaction was charged with MTBE (150 ml) and 15% ammonium chloride solution (50 ml), allowed to stir for about 30 minutes and then separated into two phases. The organic phase was washed with water (100 ml), followed by brine solution (100 ml). The organic phase was then concentrated to 50 mL and MTBE (20 ml) was added. Next, n- heptane (100 ml) was slowly added and then stirred at room temperature for about 2 hours. The reaction was then filtered, solid was washed with n-heptane and then dried under vacuum to obtain the desired product (5.0 g, yield: 76.9%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.35 (m, 5H), 5.15, 5.09 (ABq, JAB = 12.3 Hz, 2H), 4.86-4.82 (m, 1H), 4.45 (dd, = 11.1, 4.5 Hz, 1H), 4.23-4.03 (m, 2H), 3.23-3.10 (m, 1H), 2.86-2.48 (m, 4H), 2.38- 2.31 (m, 2H), 2.10-1.83 (m, 5H), 1.80-1.02 (m, 22H), 1.34 (s, 3H), 0.97 (s, 6H), 0.93 (s, 3H), 0.86 (br.s., 6H), 0.80 (m, 1H); ESI-MS: m/z 782.47 (M+Na) + .

Step 9: Synthesis of l-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-((R)-2-amino-l-hyd roxy ethyl)-l-isopropyl-5a,5b,8,8,lla-pentamethyl-2-oxo-3,3a,4,5, 5a,5b,6,7, 7a,8,9,10,ll,lla,llb, 12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)3-benzy l(lS,3R)-2,2-dimethylcyclo butane -1,3 -dicarboxylate :

To a stirred solution of 1-benzyl 3-((3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-(( ?)-l- hydroxy-2-nitroethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8, 9, 10, 11 , 11 a, 1 lb, 12, 13 , 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) ( lR,35)-2,2- dimethylcyclobutane-l,3-dicarboxylate (step 8, 6.0 g, 7.90 mmol, 1.0 eq) in methanol (120 ml) was added Nickel(II) chloride hexahydrate (2.81 g, 11.85 mmol, 1.5 eq) at -5 °C and was slowly added sodium borohydride (3.02 g, 79.0 mmol, 10.0 eq) at 5-10°C and continued for about 30 minutes. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was quenched with saturated ammonium chloride solution (50 ml) and extracted with ethyl acetate (3x100 ml). The combined organic extracts were diluted with water (150 ml), stirred at room temperature for about 16 hours. The organic layer was separated, dried over Na 2 S0 4 , filtered and evaporated under reduced pressure to obtain the desired product (5.0 g, yield: 87%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.35 (m, 5H), 5.15, 5.09 (ABq, /AB =12.3 Hz, 2H), 4.45 (dd, = 11.1, 4.5Hz, 1H), 4.0 (m, 1H), 3.22-3.09 (m, 1H), 2.86-2.73 (m, 2H), 2.70-2.45 (m, 3H), 2.40-2.20 (m, 2H), 2.15 (m, 1H), 2.05-1.02 (m, 29H), 1.34 (s, 3H), 0.96 (s, 3H), 0.94 (s, 3H), 0.92 (s, 3H), 0.86 (s, 3H), 0.85 (s, 3H), 0.79 (m, 1H); ESI-MS: m/z 730.5 (M+H) + .

Step 10: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-((R)-2-((4- chlorobenzyl) mino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,lla-pentamethyl- 2-oxo-3,3a,4,5, 5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen-9-yl) ( lR,3S)-2,2-dimethylcyclo butane- 1 ,3 -dicarboxylate:

To a stirred solution of l-((3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-(( ?)-2-amino-l- hydroxyethyl)-l-isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l, l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)3-be nzyl(15,3 ?)-2,2- dimethyl cyclobutane -1,3-dicarboxylate (step 9, 3.0 g, 4.11 mmol, 1.0 eq) in THF (70 ml) was added 4-chlorobenzaldehyde (0.518 g, 3.70 mmol, 0.9 eq) at -2 °C and continued at same temperature for about 30 minutes. Next sodium triacetoxyborohydride (1.91 g, 9.04 mmol, 2.2 eq) was added at the same temperature and then allowed to stir at room temperature for about 16 hours. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was quenched with saturated ammonium chloride solution (30 ml) and water (30 ml). The mixture was stirred at 10 to 20 °C for about 0.5 hours and then extracted with methyl ie/ -butyl ether (3x100 ml). The combined organic layers were washed with 5% potassium carbonate solution (30 ml), followed by 10% aqueous NaCl solution (2x30 ml) and then dried over sodium sulphate, filtered and evaporated under reduced pressure to obtain the desired product (3.5 g) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.40-7.30 (m, 6H), 7.25-7.15 (m, 3H), 5.15, 5.09 (ABq, JAB = 13.2 Hz, 2H), 4.50-4.40 (m, 1H), 4.08-4.0 (m, 1H), 3.64 (d, = 13.8 Hz, 1H), 3.48 (d, = 13.5 Hz, 1H), 3.23-3.05 (m, 1H), 2.85-2.72 (m, 2H), 2.72-2.55 (m, 1H), 2.50-2.12 (m, 4H), 2.12-2.0 (m, 2H), 1.95-1.0 (m, 26H), 1.34 (s, 3H), 1 -0.82 (m, 15H), 0.78 (m, 1H); ESI-MS: m/z 854.5 (M+H) + .

Step 11: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-((R)-2-((4- chlorobenzyl)(2-( dimethylamino )ethyl)amino )-l -hy droxy ethyl)- 1 -isopropyl-5a,5b,8, 8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a] chrysen- -yl) ( 1 R,3S )-2,2-dimethylcyclobutane-l ,3 -dicarboxylate :

To a stirred solution of 1-benzyl 3-((3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-(( ?)-2- ((4-chlorobenzyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8, 8,l la-pentamethyl-2-oxo-3,3a, 4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl) (1 ?,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 10, 3.5 g, 4.10 mmol, 1.0 eq) in methanol (50 ml) was added sodium 2-(dimethylamino)-l-hydroxyethane-l -sulfonate (prepared as described in WO 2007/085638, 3.89 g, 20.5 mmol, 5.0 eq) followed by triethylamine (2.0 ml, 14.36 mmol, 3.5 eq) at room temperature and heated to 40 °C for about 3 hours, then sodium cyanoborohydride (0.568 g, 9.12 mmol, 2.2 eq) was added and continued at 50 °C for about 16 hours. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (150 ml) and extracted with DCM (3x150 ml). The combined organic layers were dried over sodium sulphate, filtered and evaporated under reduced pressure to obtain the desired product (2.1 g, 55% yield) as a white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 7.38-7.32 (m, 9H), 5.12, 5.06 (ABq, /AB = 12.6 Hz, 2H), 4.38-4.32 (m, 1H), 4.03-3.86 (m, 1H), 3.72 (d, = 13.8 Hz, 1H), 3.46 (d, = 13.5 Hz, 1H), 3.15-3.0 (m, 1H), 2.97-2.80 (m, 3H), 2.75-2.56 (m, 3H), 2.45- 2.40 (m, 1H), 2.35-2.26 (m, 3H), 2.23-2.17 (m, 6H), 2.12-1.76 (m, 6H), 1.73-1.0 (m, 23H), 0.96 (s, 3H), 0.92-0.80 (m, 15H), 0.74 (m, 1H); ESI-MS: m/z 925.7 (M+H) + .

Step 12: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-((R)-2-((4- chlorobenzyl)(2-( dimethylamino )ethyl)amino )-l -hy droxy ethyl)- 1 -isopropyl-5a,5b,8, 8,11a- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H- cyclopenta[a] chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxy lic acid:

To a solution of 1-benzyl 3-((3a ?,5a ?,5b ?,7a ?,95,l la ?,l lb ?,13a5)-3a-(( ?)-2-((4- chlorobenzyl)(2-(dimethylamino)ethyl)amino)-l-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl) (1 ?,35)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 11, 2.1 g, 2.27 mmol, 1.0 eq) in MeOH (20 ml), THF (10 ml) and water (10 ml) was added potassium carbonate (4.7 g, 34.09 mmol, 15.0 eq) and stirred at room temperature for about 48 hours. The reaction mixture was evaporated under reduced pressure, diluted with water (50 ml) and pH adjusted to 7.0 with IN HC1 and extracted with DCM (3x100 ml). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 10% MeOH: DCM and 0.2% triethylamine as an eluent to obtain the desired product (50 mg) as a white solid. 1H NMR (300 MHz, CD 3 OD): δ ppm 7.36 (m, 4H), 4.47-4.38 (m, 1H), 4.13- 4.08 (m, 1H), 3.78 (d, = 14.1 Hz, 1H), 3.61 (d, = 14.1 Hz, 1H), 3.18-3.05 (m, 2H), 3.0- 2.85 (m, 3H), 2.80-2.60 (m, 2H), 2.67 (s, 6H), 2.60-2.43 (m, 3H), 2.38-2.10 (m, 4H), 2.05- 1.25 (m, 17H), 1.34 (s, 3H), 1.24-0.88 (m, 25H); ESI-MS: m/z 835.56 (M+H) + .

Example 1-2: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)- 2-(2-(4-chlorobenzamido)-2-methylpropanamido)- 1 -hydroxyethyl)- 1 -isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopentaralchrysen-9-yl)oxy)carbonyl)-2,2 -dimethylcyclobutane-l- carboxylic acid:

Step 1: Synthesis of 1-benzyl 3-((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-((R)-2-(2-(4- chlorobenzamido )-2-methylpropanamido)-l -hydroxyethyl)-! -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a] chrysen- -yl) ( 1 R,3S )-2,2-dimethylcyclobutane-l ,3 -dicarboxylate :

To a stirred solution of 2-(4-chlorobenzamido)-2-methylpropanoic acid (Intermediate 3, 0.347 g, 1.438 mmol, 1.5 eq) in DMF (14 ml) was added HBTU (0.545 g, 1.438 mmol, 1.5 eq) followed by triethylamine (0.53 ml, 3.832 mmol, 4.0 eq). The reaction mixture was stirred at room temperature for about 30 minutes, then 1- ((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-amino-l-hydroxyethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane- 1,3 -dicarboxylate (Example I-step 9, 0.700 g, 0.958 mmol, 1.0 eq) was added and stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (20 ml) and stirred at room temperature for about 20 minutes. The solid was filtered, washed with water (120 ml) and dried in vacuo. The residue was purified by silicagel column chromatography by using 0-1% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure. The obtained solid was dissolved in tert- butanol (1 ml) and toluene (1 ml), heptane (20 ml) was added and stirred at room temperature for about 30 minutes. The precipitates formed were collected by filtration and dried under vacuum to obtain the title compound (0.15 g, yield: 16.4%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.70 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.36 (m, 5H), 6.96 (t, J = 5.4 Hz, 1H), 6.65 (s, 1H), 5.14, 5.09 (ABq, AB = 12.3 Hz, 2H), 4.48-4.37 (m, 2H), 3.53 (br.s., 1H), 3.28-3.14 (m, 2H), 2.90-2.73 (m, 4H), 2.70-2.58 (m, 1H), 2.46 (d, / = 18.9 Hz, 1H), 2.36-2.22 (m, 2H), 2.09-1.0 (m, 23H), 1.63 (s, 6H), 1.34 (s, 3H), 0.96 (s, 3H), 0.92 (s, 3H), 0.90 (s, 3H), 0.88-0.76 (m, 10H); ESI-MS: m/z 976.70 (M+Na) + .

Step 2: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-((R)-2-(2-(4- chlorobenzamido )-2-methylpropanamido)-l -hydroxyethyl)-! -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobut ane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)- 2-(2-(4-chlorobenzamido)-2-methylpropanamido)-l -hydroxyethyl)- 1-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl) ( 1 R,3 S )-2,2-dimethylcyclobutane- 1,3- dicarboxylate (step 1, 0.150 g, 0.157 mmol, 1.0 eq) in MeOH (1.5 ml) and THF (1.5 ml) was added aqueous 2.5N KOH solution (0.47 ml, 1.179 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (10 ml), cooled to 0 °C, ptl adjusted to 6.0 with IN HC1 and stirred for about 15 minutes. The precipitates formed were collected by filtration, washed with water (10 ml) and dried in vacuo. The obtained solid was dissolved in DCM (20 ml), dried over sodium sulphate, filtered and concentrated under reduced pressure. The residue was washed with ethyl acetate (10 ml), acetonitrile (20 ml) was added and heated to reflux for about 30 minutes. The reaction mixture was cooled to room temperature, solids were filtered, washed with acetonitrile (5 ml) and dried under vacuum to obtain the title compound (0.03 g, yield: 22.4%) as an off-white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 12.15 (s, 1H), 8.47 (s, 1H), 7.89 (d, = 8.4 Hz, 2H), 7.67 (t, = 6.0 Hz, 1H), 7.54 (d, = 8.7 Hz, 2H), 4.70 (d, = 3.6 Hz, 1H), 4.39-4.33 (m, 1H), 4.09-4.0 (m, 1H), 3.18-3.08 (m, 1H), 2.98-2.87 (m, 2H), 2.85-2.71 (m, 3H), 2.41-2.26 (m, 3H), 2.25-2.17 (m, 1H), 2.0-1.0 (m, 26H), 1.44 (s, 3H), 1.42 (s, 3H), 1.27 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 0.88-0.78 (m, 10H); ESI-MS: m/z 887.45 (M+Na) + . Example 1-3: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)- 2-amino-l-hvdroxyethyl)-l-isopropyl-5a,5b,8,8 J la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaralchrvsen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane- 1-carboxylic acid:

To a stirred solution of l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-((R)-2-amino- 1-hydroxyethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate (Example 1-step 9, 0.6 g, 0.821 mmol, 1.0 eq) in MeOH (6 ml) and THF (6 ml) was added aqueous 2.5N KOH solution (2.47 ml, 6.164 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the organic phase was evaporated under reduced pressure. The mixture was cooled to 0 °C, and neutralized with IN HC1. The precipitates formed were collected by filtration and dried under vacuum. To this solid compound, acetonitrile (20 ml) was added and heated to reflux for about 30 minutes. The mixture was filtered at hot condition. The obtained solid was further purified by refluxing with ethyl acetate (20 ml) for about 30 minutes. The mixture was filtered at hot condition and dried under vacuum to obtain the title compound (0.120 g, yield: 22.85%) as an off-white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 4.39-4.32 (m, 1H), 4.04-3.98 (m, 1H), 3.13-3.10 (m, 3H), 2.72-2.65 (m, 4H), 2.38-1 (m, 32H), 0.97-0.77 (m, 16H); ESI-MS: m/z 638.65 (M-H) ~ .

The below compounds were prepared by procedure similar to the one described in General synthetic procedure A with appropriate variations in reactants, quantities of reagents and reaction conditions.

97

General Synthetic Procedure-B: Scheme-3:

The compounds of formula (19) can be prepared by the reaction of compounds of formula (6) with a reagent like niromethane in the presence of a base such as triethylamine (TEA) or Ν,Ν-diisopropylethylamine (DIPEA). The hydroxy group in compound (19) can be acetylated in the presence of a catalyst such as /?ara-toluenesulfonic acid monohydrate (pTSA) with a suitable reagent such as acetic anhydride or the like. The compounds of formula (21) can be prepared by chopping the acetoxy group in compound (20) in the presence of a reducing agent such as sodium borohydride (NaBH 4 ) in solvents such as methanol or combination of methanol (MeOH) and Tetrahydrofuran (THF). The acids of compounds of formula (22) can be prepared by the reaction of compounds of formula (21) with reagents such as sodium nitrite (NaN0 2 ) and acetic acid (CH 3 COOH) in a solvent such as Dimethylsulfoxide (DMSO) or the like. The amides of compounds of formula (24) can be prepared by coupling of compounds (22) and (23) in the presence of coupling reagents such as 0-(7-Azabenzotriazol- l-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HATU) or 0-(Benzotriazol-l-yl)-N,N,N\N'-tetramethyluroniumhexafluorop hosphate (HBTU) or 1- Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and 1-Hydroxybenzotriazole (HOBt) in the presence of a base such as triethylamine (TEA) or N,N-Diisopropylethylamine (DIPEA) in a suitable solvent such as Ν,Ν-dimethylformamide (DMF) or 1,2-dichloroethane (1,2-DCE). The C-3 hydroxy compound (25) can be prepared by deprotection at C-3 of compound (24) in the presence of a base such as NaOH or KOH in the combination of solvents such as MeOH, THF and H 2 0 (4:2: 1). The C-3 esters of compounds of formula (26) can be prepared by the reaction of compound (25) with compound (8) with a reagent such as 2,4,6-trichlorobenzoyl chloride, in the presence of a base such as triethylamine (TEA) or Ν,Ν-Diisopropylethylamine (DIPEA) and a catalyst such as 4-dimethylaminopyridine (DMAP) in solvents such as dichloromethane (DCM) or 1,2-dichloroethane (1,2-DCE) or the like. The ester group in compounds of formula (26) can be hydrolysed in the presence of aqueous solution of inorganic bases such as sodium hydroxide (NaOH) or potassium hydroxide (KOH) or the like in the combination of solvents such as tetrahydrofuran (THF): methanol (MeOH) (1: 1) to give compounds of formula (I). The sodium salt of compounds of formula (I) can be prepared by the reaction of compound (I) in the presence of a base such as sodium hydroxide (NaOH) in a mixture of solvents such as methanol (MeOH) and water (H 2 0).

Illustrative example of general synthetic procedure-B:

Example II-l: Preparation of sodium (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)- 3a-(2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-2-oxoe thyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahvdro-2H-cvclopentaralchrvsen-9-yl)oxy)carbonyl)-2,2 -dimethylcvclobutane-l- carboxylate:

Step 1: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(l-hydroxy-2-nitroeth yl)-l- isopropyl-5a, 5b, 8, 8, 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl acetate:

To a solution of (3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-formyl-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (Example 1-step 5, 20.0 g, 40.32 mmol, 1.0 eq) in nitromethane (73.78 g, 1209.6 mmol, 30.0 eq) was added triethylamine (19.62 ml, 141.12 mmol, 3.5 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was evaporated under reduced pressure. The crude compound was triturated with ft-hexane, precipitates formed were collected by filtration and dried under vacuum to obtain the title compound (16.0 g) as an off-white solid; ESI-MS: m/z 580.51 (M+Na) + .

Step 2: Synthesis of l-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl - 5 a, 5b, 8,8,11a -pentamethyl-2-oxo -2,3,4,5, 5 a, 5b, 6, 7, 7a, 8, 9, 10,11,1 la, lib, 12, 13, 13 a- octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)-2-nitroethyl acetate:

To a solution of (3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(l-hydroxy-2- nitroethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl acetate (step 1, 16.0 g, 28.72 mmol, 1.0 eq) in acetic anhydride (100 ml) was added /?ara-toluenesulfonic acid monohydrate (1.36 g, 7.18 mmol, 0.25 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with ethyl acetate (200 ml). The organic layer was washed with saturated sodium carbonate solution (3x100 ml) and brine solution (50 ml). The organic layer was dried over Na 2 S0 4 , filtered and evaporated under reduced pressure to obtain the title compound (16.0 g) as an off-white solid. The obtained solid compound was used as such for next step without further purification; ESI- MS: m/z 622.09 (M+Na) + .

Step 3: Synthesis of (3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-l-isopropyl-5a,5b,8,8,ll a- pentamethyl-3a-(2-nitroethyl)-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a- octadecahydro-2H-cyclopenta[a ]chrysen-9-yl acetate:

To an ice-cooled solution of l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-oxo-

2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-3aH-cyclopenta[a]chrysen- 3a-yl)-2-nitroethyl acetate (step 2, 16.0 g, 26.71 mmol, 1.0 eq) in MeOH (200 ml) and THF (40 ml) was added sodium borohydride (4.03 g, 106.84 mmol, 4.0 eq). The reaction mixture was stirred at room temperature for about 1 hour. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was quenched with water (100 ml) and extracted with ethyl acetate (3x200 ml). The combined organic layers were washed with brine solution, dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 40% ethyl acetae in hexane as an eluent to obtain the title compound (9.0 g, yield: 62.5%) as an off- white solid. ESI-MS: m/z 564.48 (M+Na) + .

Step 4: Synthesis of 2-((3aS,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-9-acetoxy-l-isopropyl- 5 a, 5b, 8,8,11a -pentamethyl-2-oxo -2,3,4,5, 5 a, 5b, 6, 7, 7a, 8, 9, 10,11,1 la, lib, 12, 13, 13 a- octadecahydro-3aH-cyclopenta[a ]chrysen-3a-yl)acetic acid:

To a stirred solution of (3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l-isopropyl- 5a,5b, 8,8,1 la-pentamethyl-3a-(2-nitroethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl acetate (step 3, 7.0 g, 12.93 mmol, 1.0 eq) in DMSO (100 ml) was added sodium nitrite (4.46 g, 64.69 mmol, 5.0 eq) and acetic acid (11.83 ml, 206.88 mmol, 16.0 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was cooled to 0 °C, ptl adjusted to 3.0 with aqueous 2N HCl and diluted with water (100 ml). The reaction mixture was extracted with ethyl acetate (3x200 ml). The combined organic layers were washed with water (100 ml), dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was triturated with n-hexane and filtered to obtain the title compound (5.4 g, yield: 79%) as an off-white solid. ESI-MS: m/z 549.45 (M+Na) + .

Step 5: Synthesis of (3aS,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-((4-chlorobenzyl)(2- (dimethylamino)ethyl)amino)-2-oxoethyl)-l-isopropyl-5a,5b,8, 8,lla-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl acetate:

To a stirred solution of 2-((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-οχο-

2,3,4,5, 5a,5b,6,7,7a,8, 9, 10, 11, 11a, l ib, 12,13, 13a-octadecahydro-3aH-cyclopenta[a]chrysen- 3a-yl)acetic acid (step 4, 2.4 g, 4.56 mmol, 1.0 eq) in DMF (10 ml) were added HBTU (2.59 g, 6.84 mmol, 1.5 eq) followed by DIPEA (3.96 ml, 22.81 mmol, 5.0 eq). The reaction mixture was stirred at room temperature for about 10 minutes, then N 1 -(4-chlorobenzyl)- N 2 ,N 2 -dimethylethane-l,2-diamine (Intermediate 1, 1.45 g, 6.84 mmol, 1.5 eq) in DMF (20 ml) was added and stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (200 ml) and extracted with ethyl acetate (3x100 ml). The combined organic extracts were dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 1% MeOH in DCM as an eluent to obtain the title compound (1.8 g, yield: 55%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.36 (d, = 8.1 Hz, 2H), 7.11 (d, = 8.4 Hz, 2H), 4.59-4.46 (m, 3H), 3.55-

3.49 (m, 1H), 3.32-3.23 (m, 1H), 3.20-3.10 (m, 1H), 3.0-2.60 (m, 2H), 2.57- 2.47 (m, 2H),

2.50 (s, 3H), 2.46-2.27 (m, 3H), 2.21 (s, 3H), 2.20-2.10 (m, 1H), 2.05 (s, 3H), 2.0-1.0 (m, 22H), 0.98-0.76 (m, 16H); ESI-MS: m/z 721.53 (M+H) + .

Step 6: Synthesis of N-(4-chlorobenzyl)-N-(2-(dimethylamino)ethyl)-2- ( ( 3aS, 5aR, 5bR, 7aR, 9S, 11 aR, 11 bR, 13aS ) -9-hydroxy-l -isopropyl-5a, 5b, 8, 8, 1 la-pentamethyl- 2 -oxo -2, 3, 4, 5, 5 a, 5b, 6,7, 7a,8,9,10,ll,lla,llb,12,13,13a -octadecahydro -3aH- cyclopenta[a]chrysen-3a-yl)acetamide:

To a stirred solution of (3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((4- chlorobenzyl)(2-(dimethylamino)ethyl)amino)-2-oxoethyl)-l-is opropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl acetate (step 5, 1.8 g, 2.5 mmol, 1.0 eq) in MeOH (20 ml), THF (10 ml) and water (5 ml) at 0 °C was added NaOH (2.0 g, 50.0 mmol, 20.0 eq). The reaction mixture was allowed to stir at room temperature for about 6 hours. TLC indicated starting material was consumed and the desired product was observed. The organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (50 ml) and extracted with DCM (3x100 ml). The combined organic extracts were washed with water (50 ml), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 5% MeOH in DCM as an eluent to obtain the title compound (1.0 g, yield: 59%) as a white solid. 1H NMR (300 MHz, CDCI3): δ ppm 7.35 (d, = 8.4 Hz, 2H), 7.11 (d, = 8.4 Hz, 2H), 4.58-4.51 (m, 2H), 3.61- 3.42 (m, 1H), 3.32-3.09 (m, 3H), 2.93-2.62 (m, 2H), 2.57-2.47 (m, 2H), 2.43-2.38 (m, 2H), 2.36-2.25 (m, 1H), 2.31 (s, 3H), 2.21 (s, 3H), 2.15 (d, = 18.9 Hz, 1H), 2.0-1.0 (m, 22H), 1.0-0.66 (m, 16H); ESI-MS: m/z 679.51 (M+H) + . Step 7: Synthesis of l-benzyl3-((3aS,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-((4- chlorobenzyl)(2-( dimethylamino )ethyl)amino )-2-oxoethyl)-l -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a] chryse -9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of N-(4-chlorobenzyl)-N-(2-(dimethylamino)ethyl)-2- ((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-hydroxy-l-isopropyl-5a,5b,8,8,l la-pentamethyl- 2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-3aH- cyclopenta[a]chrysen-3a-yl)acetamide (step 6, 1.0 g, 1.47 mmol, 1.0 eq) and (lS,3R)-3- ((benzyloxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylicac id (prepared as described in WO 2011/007230 A2, 0.57 g, 2.21 mmol, 1.5 eq) in DCM (15 ml) at 0 °C were added triethylamine (1.02 ml, 7.35 mmol, 5.0 eq), DMAP (0.089 g, 0.73 mmol, 0.5 eq) and 2,4,6- trichlorobenzoyl chloride (0.34 ml, 2.21 mmol, 1.5 eq). The reaction mixture was flushed with nitrogen and allowed to stir at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (50 ml) and extracted with DCM (3x50 ml). The combined organic extracts were washed with water (25 ml), dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 3% MeOH in DCM as an eluent to obtain the title compound (1.2 g, yield: 88.8%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.35 (d, = 8.4 Hz, 2H), 7.35 (m, 5H), 7.11 (d, = 8.4 Hz, 2H), 5.15, 5.09 (ABq, = 12.3 Hz 2H), 4.60-4.41 (m, 3H), 3.60-3.40 (m, 1H), 3.33- 3.25 (m, 1H), 3.20-3.08 (m, 1H), 2.92-2.60 (m, 5H), 2.58-2.47 (m, 2H), 2.43-2.32 (m, 2H), 2.29 (s, 3H), 2.21 (s, 3H), 2.17-1.0 (m, 25H), 1.34 (s, 3H), 1.0-0.78 (m, 19H); ESI-MS: m/z 923.77 (M+H) + .

Step 8: Synthesis of (lR,3S)-3-((((3aS,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-((4- chlorobenzyl)(2-( dimethylamino )ethyl)amino )-2-oxoethyl)-l -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3, 3 a, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobut ane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10, l 1, 1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane- l,3-dicarboxylate (step 7, 1.2 g, 1.30 mmol, 1.0 eq) in MeOH (25 ml) and THF (25 ml) was added aqueous 2.5N KOH solution (3.89 ml, 9.76 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (30 ml), cooled to 0 °C, pH adjusted to 6.0 with IN HC1 and extracted with DCM (3x100 ml). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 8% MeOH in DCM as an eluent to obtain the title compound (0.3 g, yield: 28%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.34 (d, = 8.4 Hz, 2H), 7.09 (d, = 8.1 Hz, 2H), 4.62-4.40 (m, 3H), 3.60-3.54 (m, 1H), 3.40-3.28 (m, 1H), 3.20-3.08 (m, 1H), 2.97-2.50 (m, 6H), 2.40 (s, 6H), 2.28-2.22 (m, 3H), 2.20- 1.02 (m, 25H), 1.33 (s, 3H), 1.01-0.78 (m, 19H); ESI-MS: m/z 833.68 (M+H) + .

Step 9: Synthesis of sodium (lR,3S)-3-((((3aS,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-((4- chlorobenzyl)(2-( dimethylamino )ethyl)amino )-2-oxoethyl)-l -isopropyl-5a,5b, 8,8,11a- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobut ane-l-carboxylate:

To a stirred solution of (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-2-oxoethyl)- l-isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10, l 1, 1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobut ane-l-carboxylic acid (step 8, 0.28 g, 0.336 mmol, 1.0 eq) in MeOH (3 ml) and water (0.1 ml) was added sodium hydroxide (0.013 g, 0.336 mmol, 1.0 eq). The reaction mixture was stirred at room temperature for about 2 hours and then distilled out about 90% methanol under reduced pressure. Hexane (5 ml) and ethyl acetate (5 ml) were added and the reaction mixture was stirred at room temperature for overnight. The reaction mixture was filtered, solid was washed with hexane (5 ml) followed by ethyl acetate (5 ml) and dried under vacuum to obtain the title compound (0.160 g, yield: 55%) as a white solid. 1H NMR (300 MHz, CD 3 OD): δ ppm 7.42 (d, = 8.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), Ί .25-1.11 (m, 2H), 4.70-4.38 (m, 3H), 3.60-3.40 (m, 2H), 3.28-3.15 (m, 1H), 3.02-2.80 (m, 1H), 2.80-2.59 (m, 4H), 2.58-2.38 (m, 4H), 2.26 (s, 6H), 2.18-1.08 (m, 28H), 1.33 (s, 3H), 1.06-0.81 (m, 16H); ESI-MS: m/z 833.54 (M+H) + .

Example II-2: Preparation of sodium (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)- 3a-(2-(((l-(4-chlorophenyl)cyclopropyl)methyl)(2-(dimethylam ino)ethyl)amino)-2- oxoethyl)-l-isopropyl-5a,5b,8,8 J la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaralchrvsen- 9-yl)oxy)carbonyl)-2, -dimethylcvclobutane-l-carboxylate:

Step 1: Synthesis of (3aS,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(((l-(4- chlorophenyl)cyclopropyl)methyl)(2-(dimethylamino)ethyl)amin o

5 a, 5b, 8,8,11a -pentamethyl-2-oxo -3,3 a, 4, 5, 5 a, 5b, 6,7, 7a, 8, 9, 10,11,1 la, lib, 12, 13, 13 a- octadecahydro-2H-cyclopenta[a ]chrysen-9-yl acetate:

To a stirred solution of 2-((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-acetoxy-l- isopropyl-5a,5b,8,8,l la-pentamethyl-2-οχο-

2,3,4,5, 5a,5b,6,7,7a,8, 9, 10, 11, 11a, l ib, 12,13, 13a-octadecahydro-3aH-cyclopenta[a]chrysen- 3a-yl)acetic acid (Example 2-step 4, 2.3 g, 4.366 mmol, 1.0 eq) in DMF (25 ml) was added HATU (2.48 g, 6.549 mmol, 1.5 eq) followed by DIPEA (2.98 ml, 17.464 mmol, 4.0 eq). The reaction mixture was stirred at room temperature for about 10 minutes, then N 1 -((l-(4- chlorophenyl)cyclopropyl)methyl)-N 2 ,N 2 -dimethylethane-l,2-diamine (Intermediate 2, 1.32 g, 5.239 mmol, 1.2 eq) was added and stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was combined with another 200 mg batch of same reaction, diluted with water (350 ml) and extracted with ethyl acetate (3x50 ml). The combined organic extracts were washed with water (100 ml), dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-4% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (2.5 g, yield: 69.25%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.25-7.20 (m, 4H), 4.53-4.45 (m, 1H), 3.87-3.80 (m, 1H), 3.78-3.47 (m, 2H), 3.36-3.31 (m, 1H), 3.22-3.15 (m, 2H), 2.45-2.37 (m, 3H), 2.30-2.20 (m, 2H), 2.16 (s, 6H), 2.05 (s, 3H), 2.0-1.05 (m, 28H), 0.97-0.78 (m, 16H); ESI-MS: m z 761.44 (M+H) + .

Step 2: Synthesis of N-((l-(4-chlorophenyl)cyclopropyl)methyl)-N-(2-(dimethylamin o)ethyl)- 2-(( 3aS, 5aR, 5bR, 7aR, 9S, 11 aR, 11 bR, 13aS)-9-hydroxy-l -isopropyl-5a, 5b, 8,8,11a- pentamethyl-2-oxo-2, 3, 4, 5, 5 a, 5b, 6, 7, 7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-3aH- cyclopenta[a]chrysen-3a-yl)acetamide:

To a stirred solution of (3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(((l-(4- chlorophenyl)cyclopropyl)methyl)(2-(dimethylamino)ethyl)amin o)-2-oxoethyl)-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl acetate (step 1, 2.5 g, 3.282 mmol, 1.0 eq) in MeOH (88 ml), THF (44 ml) and water (22 ml) at 0 °C was added NaOH (1.96 g, 49.24 mmol, 15.0 eq). The reaction mixture was removed from the ice bath and was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (50 ml) and extracted with DCM (3x50 ml). The combined organic extracts were washed with water (50 ml) and brine solution (50 ml). The organic layer was dried with sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-7% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (2.2 g, yield: 93.22%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.25-7.20 (m, 4H), 3.87-3.82 (m, 1H), 3.56-3.51 (m, 1H), 3.37-3.31 (m, 1H), 3.25-3.18 (m, 1H), 3.17-3.07 (m, 2H), 2.82-2.73 (m, 1H), 2.70- 2.62 (m, 1H), 2.27-2.21 (m, 4H), 2.16 (s, 3H), 2.12-1.05 (m, 31H), 1.0-0.68 (m, 16H); ESI- MS: m/z 719.40 (M+H) + .

Step 3: Synthesis of 1-benzyl 3-((3aS,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(((l-(4- chlorophenyl)cyclopropyl)methyl)(2-(dimethylamino)ethyl)amin o

5 a, 5b, 8,8,11a -pentamethyl-2-oxo -3,3 a, 4, 5, 5 a, 5b, 6,7, 7a, 8, 9, 10,11,1 la, lib, 12, 13, 13 a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3- dicarboxylate:

To a stirred solution of N-((l-(4-chlorophenyl)cyclopropyl)methyl)-N-(2- (dimethylamino)ethyl)-2-((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-9-hydroxy-l-isopropyl- 5a,5b,8,8,l la-pentamethyl-2-oxo-2,3,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a- octadecahydro-3aH-cyclopenta[a]chrysen-3a-yl)acetamide (step 2, 2.4 g, 3.335 mmol, 1.0 eq ) in DCM (30 ml) at 0 °C under nitrogen atmosphere were added (lS,3R)-3- ((benzyloxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (prepared as described in WO 2011/007230 A2, 1.30 g, 4.99 mmol, 1.5 eq), triethylamine (1.39 ml, 9.99 mmol, 3.0 eq), DMAP (0.2 g, 1.66 mmol, 0.5 eq) and 2,4,6-trichlorobenzoyl chloride (0.77 ml, 4.99 mmol, 1.5 eq). The reaction mixture was removed from the ice bath and was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (25 ml) and extracted with DCM (3x30 ml). The combined organic extracts were washed with 0.5N HC1 (15 ml), water (30 ml) and brine solution (10 ml). The organic layer was dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 3-4% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.8 g, yield: 56%) as an off-white solid. 1H NMR (300 MHz, CDCI3): δ ppm 7.37-7.33 (m, 5H), 7.26 (d, = 9.0 Hz, 2H), 7.19 (d, = 8.4 Hz, 2H), 5.15, 5.09 (ABq, JAB = 12.6 Hz , 2H), 4.48-4.42 (m, 1H), 3.87-3.76 (m, 1H), 3.65-3.57 (m, 1H), 3.37-3.29 (m, 1H), 3.20-3.08 (m, 2H), 2.86-2.73 (m, 3H), 2.70-2.58 (m, 3H), 2.48 (s, 3H), 2.30-2.22 (m, 2H), 2.18 (s, 3H), 2.12-1.98 (m, 3H), 1.98-1.0 (m, 30H), 1.0-0.78 (m, 19H); ESI-MS: m/z 963.53 (M+H) + .

Step 4: Synthesis of (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(((l- (4- chlorophenyl)cyclopropyl)methyl)(2-(dimethylamino)ethyl)amin o)-2-oxoethyl)-l-isopropyl- 5 a, 5b, 8,8,11a -pentamethyl-2-oxo -3,3 a, 4, 5, 5 a, 5b, 6,7, 7a, 8, 9, 10,11,1 la, lib, 12, 13,13 a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2 -dimethylcyclobutane-l- carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (((l-(4-chlorophenyl)cyclopropyl)methyl)(

isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (0.2 g, 0.207 mmol, 1.0 eq) in MeOH (4 ml) and THF (4 ml) was added aqueous 2.5N KOH solution (0.62 ml, 1.552 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The organic phase was evaporated under reduced pressure, reaction mixture was diluted with water (10 ml), cooled to 0 °C, pU adjusted to 6.0 with IN HCl and extracted with DCM (3x25 ml). The combined organic extracts were washed with water (10 ml), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-8% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.135 g, yield: 74.4%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.27 (d, = 8.4 Hz, 2H), 7.21 (d, = 8.4 Hz, 2H), 4.53-4.45 (m, 1H), 3.85-3.76 (m, 1H), 3.62-3.55 (m, 1H), 3.39-3.30 (m, 1H), 3.20-2.85 (m, 4H), 2.86-2.74 (m, 2H), 2.72-2.50 (m, 3H), 2.43 (s, 3H), 2.38-2.22 (m, 2H), 2.20 (s, 3H), 2.14-1.04 (m, 32H), 0.98-0.78 (m, 19H); ESI-MS: m/z 873.51 (M+H) + .

Step 5: Synthesis of sodium (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(((l- (4-chlorophenyl)cyclopropyl)methyl)(2-(dimethylamino)ethyl)a mino)-2-oxoethyl)-l- isopropyl-5a, 5b, 8, 8, 11 a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylate:

To a stirred solution of (lR,3S)-3-((((3aS,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- (((l-(4-chlorophenyl)cyclopropyl)methyl)(2-(dimethylamino)et hyl)amino)-2-oxoethyl)- isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (step 4, 0.11 g, 0.125 mmol, 1.0 eq) in MeOH (3 ml) and water (0.08 ml) was added sodium hydroxide (0.005 g, 0.137 mmol, 1.1 eq). The reaction mixture was stirred at room temperature for about 2 hours, then distilled out methanol under reduced pressure. Hexane (5 ml) and ethyl acetate (5 ml) were added and the reaction mixture was stirred at room temperature for overnight. The reaction mixture was filtered, solid was washed with hexane and ethyl acetate (5 ml) and dried under vacuum to obtain the title compound (0.06 g, yield: 53.2%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.30-7.18 (m, 4H), 4.38 (m, IH), 3.90-3.82 (m, IH), 3.68-3.50 (m, IH), 3.40-3.30 (m, 3H), 2.90-2.32 (m, 9H), 2.25-2.0 (m, 9H), 2.0-1.0 (m, 29H), 1.0-0.70 (m, 19H); ESI-MS: m/z 873.51 (M+H) + .

The below compounds were prepared by procedure similar to the one described in General synthetic procedure B with appropriate variations in reactants, quantities of reagents and reaction conditions. The physiochemical characteristics of the compounds are summarized herein below table.

Π-56 790.47

ΟΗ

Π-57 802.47

OH

Π-58 830.50

OH

Π-59 803.47

OH

Π-60 764.46

OH

Π-61 742.50

OH

Π-62 756.51

863.57

Π-235

ΟΗ

862.59

Π-236

ΟΗ

General Synthetic Procedure-C:

Scheme-4:

Scheme-4

The compounds of formula (27) can be prepared by the reaction of compounds of formula (9) with a reagent like niromethane in the presence of a base such as triethylamine (TEA) or Ν,Ν-diisopropylethylamine (DIPEA). The hydroxy group in compound (27) can be acetylated in the presence of a catalyst such as /?ara-toluenesulfonic acid monohydrate (pTSA) with a suitable reagent such as acetic anhydride to give compound (28). The compounds of formula (29) can be prepared by chopping the acetoxy group in compound (28) in the presence of a reducing agent such as sodium borohydride (NaBH 4 ) in solvents such as methanol or combination of methanol (MeOH) and Tetrahydrofuran (THF). The amines of compounds of formula (30) can be prepared by reducing the nitro group in compounds of formula (29) with a reagent such as Nickel(II) chloride hexahydrate (NiCl 2 -6H 2 0) and reducing agent such as sodium borohydride (NaBH 4 ) in the combination of solvents such as methanol (MeOH) and dichloromethane (DCM) or methanol (MeOH) and tetrahydrofuran (THF). The compounds of formula (32) can be prepared by coupling of compounds (30) and (31) with coupling reagents such as 0-(7-Azabenzotriazol-l-yl)- Ν,Ν,Ν',Ν'-tetramethyluroniumhexafluorophosphate (HATU) or O-(Benzotriazol-l-yl)- Ν,Ν,Ν',Ν'-tetramethyluroniumhexafluorophosphate (HBTU) or l-Ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDCI) and 1-Hydroxybenzotriazole (HOBt) in the presence of a base such as triethylamine (TEA) or Ν,Ν-Diisopropylethylamine (DIPEA) in a suitable solvent such as Ν,Ν-dimethylformamide (DMF) or 1,2-dichloroethane (1,2-DCE).

Alternative reductive amination of compound (30) and (33) in the presence of acetic acid and STAB in a suitable solvent such as 1,2-dicloroethane or DCM or the like to give compound of formula (32).

More alternatively the compounds of formula (34) can be prepared by the reaction of compound 29 with KMn0 4 , MgS0 4 and aq. KOH solution in the presence of acetone and methanol. The obtained compound (34) further undergoes reductive amination with compound 35 in the presence of acetic acid and STAB in solvents like 1,2-dichloroethane and the like to give compound of formula (32).

The compounds of formula (I) can be prepared by hydrolysing the ester group in compounds of formula (32) in the presence of aqueous solution of inorganic bases such as sodium hydroxide (NaOH) or potassium hydroxide (KOH) or the like in the combination of solvents such as tetrahydrofuran (THF): methanol (MeOH) or the like.

* Upon requirement, any of the compounds of the above scheme can form HC1 salt in the presence of acidic medium such as HC1 in 1,4-dioxane or HC1 in MeOH or the like. Illustrative example of general synthetic procedure-C:

Example III- 1 : Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2- (4-chlorobenzamido)-2-methylpropanamido)ethyl)- l-isopropyl-5a,5b,8,8 J la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H- cyclopentaralchryse -9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

Step 1: Synthesis of 1-benzyl 3-((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(l-hydroxy-2- nitroethyl)-l-isopropyl-5a,5b,8,8,lla-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-formyl-l-iso propyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8, 9, 10,11,1 la,l lb, 12,13, 13a- octadecahydro-2H-cyclopenta[a]chrysen-9-yl)(lR,3S)-2,2-dimet hylcyclobutane-l,3- dicarboxylate (Example 1-step 7, 6.0 g, 8.587 mmol, 1.0 eq) in nitromethane (14 ml, 257.62 mmol, 30 eq) was added triethylamine (4.18 ml, 30.05 mmol, 3.5 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was evaporated under reduced pressure. The crude compound was triturated with n-hexane (50 ml), solid was filtered and dried under vacuum to obtain the title compound (5.0 g, yield: 76.6%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.35 (m, 5H), 5.15, 5.09 (ABq, AB = 12.3 Hz, 2H), 4.95- 4.82 (m, 1H), 4.60-4.30 (m, 1H), 4.20-4.03 (m, 2H), 3.25-3.10 (m, 2H), 2.98-2.73 (m, 2H), 2.70-2.41 (m, 3H), 2.40-2.12 (m, 1H), 2.09-2.01 (m, 2H), 2.0-1.02 (m, 22H), 1.34 (s, 3H), 1.0-0.78 (m, 19H).

Step 2: Synthesis of l-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(l-acetoxy-2-nitro ethyl)- 1 -isopropyl-5a,5b, 8,8,11 a-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl) 3 -benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(l- hydroxy-2-nitroethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 1, 5.0 g, 6.578 mmol, 1.0 eq) in acetic anhydride (32 ml) was added /?ara-toluenesulfonic acid monohydrate (0.312 g, 1.644 mmol, 0.25 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was evaporated under reduced pressure, diluted with water (100 ml) and extracted with ethyl acetate (2x100 ml). The combined organic extracts were washed with saturated sodium bicarbonate solution, dried over Na 2 S0 4 , filtered and evaporated under reduced pressure to obtain the title compound (3.5 g) as an off-white solid. ESI-MS: m/z 824.52 (M+Na) + .

Step 3: Synthesis of 1-benzyl 3-((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-l-isopropyl- 5a,5b,8,8,lla-pentamethyl-3a-(2-nitroethyl)-2-oxo-

3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl) ( lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To an ice-cold solution of l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(l-acetoxy- 2-nitroethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 2, 3.5 g, 4.363 mmol, 1.0 eq) in methanol (35 ml) and THF (5 ml) was added sodium borohydride (0.660 g, 17.455 mmol, 4.0 eq). The reaction mixture was stirred at room temperature for about 1 hour. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was quenched by the addition of water (30 ml) and extracted with ethyl acetate (2x100 ml). The combined organic layers were washed with brine solution (20 ml), dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 25-30% ethyl acetae in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (2.2 g, yield: 67.9%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.35 (m, 5H), 5.15, 5.10 (ABq, JAB = 12.3 Hz, 2H), 4.45 (dd, = 11.7, 5.1 Hz, 1H), 4.27-4.04 (m, 2H), 3.22-3.10 (m, 1H), 2.87-2.47 (m, 5H), 2.26-2.17 (m, 2H), 2.12-1.98 (m, 2H), 1.98-1.0 (m, 23H), 1.34 (s, 3H), 0.93 (s, 6H), 0.88-0.78 (m, 13H); ESI-MS: m z 766.66 (M+Na) + .

Step 4: Synthesis of l-((3aR,5aR,5bR, 7aR,9S,llaR,llbR,13aS)-3a-(2-aminoethyl)-l- isopropylSa, 5b, 8, 8, 11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl) 3 -benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-l- isopropyl- 5a,5b,8,8,l l a-pentamethyl- 3 a- (2-nitroethyl) -2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (2.2 g, 2.956 mmol, 1.0 eq) in methanol (25 ml) and DCM (5 ml) was added Nickel(II) chloride hexahydrate (1.05 g, 4.435 mmol, 1.5 eq) at -5 °C and was slowly added sodium borohydride (1.118 g, 29.56 mmol, 10.0 eq) at -5 °C. The reaction mixture was stirred at -5 °C for 30 minutes. TLC indicated starting material was consumed and the desired product was observed. The mixture was then quenched with saturated ammonium chloride solution (50 ml), diluted with EtOAc (100 ml) and stirred at room temperature for overnight. The organic layer was separated, washed with saturated ammonium chloride (50 ml), water (50 ml) and brine solution (20 ml). The organic layer was dried over Na 2 S0 4 , filtered and evaporated under reduced pressure to obtain the title compound (1.4 g, yield: 66.3%) as an off-white solid. 1H NMR (300 MHz, CDCI 3 ): δ ppm 7.34 (m, 5H), 5.12, 5.07 (ABq, AB = 12.6 Hz, 2H), 4.39 (dd, = 10.2, 5.4 Hz, 1H), 3.30-3.15 (m, 1H), 2.90-2.72 (m, 3H), 2.60-2.50 (m, 4H), 2.43-2.10 (m, 2H), 2.10-1.08 (m, 25H), 1.33 (s, 3H), 1.0-0.78 (m, 19H); ESI-MS: m/z 736.66 (M+Na) + .

Step 5: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(2-(4- chlorobenzamido)-2-methylpropanamido)ethyl)-l-isopropyl-5a,5 b,8,8,lla-pentamethyl-2- oxo -3,3 a, 4, 5, 5 a, 5b, 6, 7,7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a] chrysen-9- -2,2-dimethylcyclobutane-l ,3 -dicarboxylate :

To a stirred solution of 2-(4-chlorobenzamido)-2-methylpropanoic acid (Intermediate 3, 0.4738 g, 1.960 mmol, 1.0 eq) in DMF (25 ml) was added HBTU (1.114 g, 2.941 mmol, 1.5 eq) followed by TEA (1.09 ml, 7.84 mmol, 4.0 eq). The reaction mixture was stirred at room temperature for about 30 minutes, then l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a- (2-aminoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 4, 1.4 g, 1.96 mmol, 1.0 eq) was added and stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (50 ml) and extracted with ethyl acetate (2x30 ml). The combined organic extracts were washed with water (50 ml), dried over Na 2 S0 4 , filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 70- 80% ethyl acetae in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.800 g, yield: 43.7%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.73 (d, = 8.4 Hz, 2H), 7.41 (d, = 8.7 Hz, 2H), 7.35 (m, 5H), 6.94 (s, 1H), 6.45 (t, = 5.4 Hz, 1H), 5.15, 5.10 (ABq, J AB = 12.3 Hz, 2H), 4.45 (dd, = 11.1, 4.5 Hz, 1H), 3.22-3.0 (m, 3H), 2.90-2.53 (m, 5H), 2.31 (d, = 18.9 Hz, 1H), 2.10-1.0 (m, 35H), 1.34 (s, 3H), 0.96 (s, 3H), 0.91 (s, 6H), 0.85 (s, 6H), 0.78 (m, 1H); ESI-MS: m/z 959.72 (M+Na) + .

Step 6: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(2-(4 - chlorobenzamido)-2-methylpropanamido)ethyl)-l-isopropyl-5a,5 b,8,8,lla-pentamethyl-2- oxo -3,3 a, 4, 5, 5 a, 5b, 6, 7,7a,8,9,10,ll,lla,llb,12,13,l 3a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobut ane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2- (4-chlorobenzamido)-2-methylpropanamido)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2- oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 5, 0.800 g, 0.853 mmol, 1.0 eq) in MeOH (8 ml) and THF (8 ml) was added aqueous 2.5N KOH solution (2.56 ml, 6.4 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The organic phase was evaporated under reduced pressure, the reaction mixture was diluted with water (10 ml), cooled to 0 °C, ptl adjusted to 5.0 with IN HCl and extracted with DCM (3x50 ml). The combined organic extracts were washed with water (50 ml), dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 80-95% ethyl acetae in hexane gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the solid. To this solid compound, acetonitrile (10 ml) was added and heated to reflux for about 20 minutes. The mixture was slowly cooled to 0 °C, solid was filtered and dried under vacuum to obtain the title compound (250 mg, yield: 34.9%) as a white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.73 (d, = 8.7 Hz, 2H), 7.41 (d, = 8.4 Hz, 2H), 7.0 (s, 1H), 6.47 (t, = 5.4 Hz, 1H), 4.46 (dd, = 11.1, 4.8 Hz, 1H), 3.22-3.0 (m, 3H), 2.90-2.75 (m, 3H), 2.64-2.52 (m, 2H), 2.31 (d, = 18.6 Hz, 1H), 2.10-1.01 (m, 26H), 1.67 (s, 6H), 1.37 (s, 3H), 1.06 (s, 3H), 0.91 (s, 6H), 0.9-0.78 (m, 10H); ESI-MS: m/z 869.66 (M+Na) + .

Example III-2: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- aminoethyl)-l-isopropyl-5a,5b,8,8 J la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaralchrvsen- 9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane- 1-carboxylic acid hydrochloride:

Step 1: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-((tert- butoxycarbonyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,lla-pentam ethyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- aminoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate (Example 4-step 4, 0.7 g, 0.980 mmol, 1.0 eq) in DCM (14 ml) were added TEA (0.54 ml, 3.921 mmol, 4.0 eq) and di- tert-buty\ dicarbonate (0.427 g, 1.960 mmol, 2.0 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction monitored by TLC, the reaction mixture was diluted with ethyl acetate (100 ml). The organic layer was washed with 0.5N HCl (50 ml), water (50 ml) and brine solution (50 ml). The organic layer was dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-2% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.650 g, yield: 81.4%) as an off-white solid. 1H NMR (300 MHz, CDCI 3 ): δ ppm 7.35 (m, 5H), 5.15, 5.09 (ABq, AB = 12.6 Hz, 2H), 4.45 (dd, J = 11.4, 4.8 Hz, 1H), 3.21-3.10 (m, 1H), 3.03 (br.s., 1H), 2.86-2.73 (m, 4H), 2.70-2.58 (m, 1H), 2.28 (d, = 18.9 Hz, 1H), 2.08-2.0 (m, 2H), 1.98-1.0 (m, 29H), 1.43 (s, 9H), 1.34 (s, 3H), 0.96 (s, 3H), 0.92 (s, 3H), 0.91 (s, 3H), 0.88-0.78 (m, 7H); ESI-MS: m/z 836.6 (M+Na) + .

Step 2: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-((ter t- butoxycarbonyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,lla-pentam ethyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid'.

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((tert-butoxycarbonyl)amino)ethyl)-l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 1, 0.650 g, 0.798 mmol, 1.0 eq) in MeOH (6.5 ml) and THF (6.5 ml) was added aqueous 2.5N KOH solution (2.39 ml, 5.987 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction monitored by TLC, the reaction mixture was evaporated under reduced pressure. The mixture was cooled to 0 °C, water (10 ml) was added, acidified with IN HC1 to pU = 5.0 and extracted with DCM (2x100 ml). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-5% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.4 g, yield: 69.2%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 4.47 (dd, = 11.1, 4.5 Hz, 1H), 3.21-3.10 (m, 1H), 3.03 (br.s., 1H), 2.86-2.75 (m, 4H), 2.70-2.58 (m, 1H), 2.28 (d, = 18.9 Hz, 1H), 2.08-2.0 (m, 2H), 1.98-1.03 (m, 29H), 1.43 (s, 9H), 1.37 (s, 3H), 1.08 (s, 3H), 0.93 (s, 3H), 0.92 (s, 3H), 0.90-0.78 (m, 7H); ESI-MS: m/z 746.50 (M+Na) + .

Step 3: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-amino ethyl)- 1 -isopropyl-5a,5b, 8,8,11 a-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid hydrochloride'.

To a solution of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((tert- butoxycarbonyl)amino)ethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (step 2, 0.2 g, 0.276 mmol, 1.0 eq) in 1,4- dioxane (1.25 ml) at 0 °C was added 4N HC1 in 1,4-dioxane (3.75 ml). The reaction mixture was stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was concentrated under reduced pressure, washed with MTBE (30 ml) and hexane (30 ml). The resulting solid was refluxed with MTBE (30 ml) for about 1 hour. The mixture was cooled to room temperature, filtered, solid was washed with MTBE (20 ml) and dried under vacuum to obtain the title compound (0.055 g, yield: 30.1%) as an off-white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 12.17 (s, 1H), 7.84 (br.s., 3H), 4.39-4.34 (m, 1H), 3.20-3.10 (m, 1H), 2.85-2.72 (m, 3H), 2.64-2.53 (m, 2H), 2.47-2.36 (m, 2H), 2.32-2.20 (m, 2H), 1.96 (d, = 19.2 Hz, 1H), 1.82-1.0 (m, 27H), 1.34 (s, 3H), 0.94-0.80 (m, 16H); ESI-MS: m/z 624.40 (M+H) + .

Example III-3: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2- amino-2-methylpropanamido)ethyl)-l-isopropyl-5a,5b,8,8 J la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaralchrvsen- 9-yl)oxy)carbonyl)-2,2-dimethylcvclobutane- 1-carboxylic acid hydrochloride:

Step 1: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(2-((tert- butoxycarbonyl)amino)-2-methylpropanamido)ethyl)-l-isopropyl -5a,5b,8,8,lla-pentamethyl- 2 -oxo-3, 3 a, 4, 5, 5 a, 5b, 6,7, 7a,8,9,10,ll,lla,llb,12,13,13a -octadecahydro -2H- cyclopenta[a] chrysen- -yl) ( 1 R,3S )-2,2-dimethylcyclobutane-l ,3 -dicarboxylate :

To a stirred solution of 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid (Intermediate 4, 0.426 g, 2.10 mmol, 1.5 eq) in DMF (10 ml) were added HBTU (0.796 g, 2.10 mmol, 1.5 eq) and triethylamine (0.59 ml, 4.20 mmol, 3.0 eq). The reaction mixture was stirred at room temperature for 30 minutes, then l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)- 3a-(2-aminoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate (Example 4-step 4, 1.0 g, 1.400 mmol, 1.0 eq) was added and stirred at room temperature for overnight. TLC indicated starting material was consumed and the desired product was observed. The reaction mixture was diluted with water (150 ml) and stirred at room temperature for about 30 minutes. The precipitates formed were collected by filtration, washed with water (50 ml) and dried under vacuum. The obtained solid was purified by silicagel column chromatography by using 2% MeOH in DCM eluent. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (1.0 g, yield: 80%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.36-7.33 (m, 5H), 6.50 (s, 1H), 5.15, 5.09 (ABq, AB = 12.3 Hz, 2H), 4.84 (s, 1H), 4.45 (dd, = 11.1, 4.5 Hz, 1H), 3.21-3.11 (m, 1H), 3.04-2.88 (m, 3H), 2.87-2.73 (m, 3H), 2.70-2.58 (m, 1H), 2.31 (d, = 18.9 Hz, 1H), 2.09-1.99 (m, 2H), 1.97-1.09 (m, 33H), 1.43 (s, 9H), 1.34 (s, 3H), 0.98-0.78 (m, 16H); ESI- MS: m/z 921.6 (M+Na) + .

Step 2: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,nbR,13aS)-3a-(2-(2-((t ert- butoxycarbonyl)amino)-2-methylpropanamido)ethyl)-l-isopropyl -5a,5b,8,8,lla-pentamethyl- 2 -oxo-3, 3 a, 4, 5, 5 a, 5b, 6,7, 7a,8,9,10,ll,lla,llb,12,13,13a -octadecahydro -2H- cyclopenta[a]chryse -9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-

((tert-butoxycarbonyl)amino)-2-methylpropanamido)ethyl)-l -isopropyl-5a,5b, 8,8,1 la- pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l 1,1 la,l lb, 12,13, 13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 1, 1.0 g, 1.112 mmol, 1.0 eq) in MeOH (10 ml) and THF (10 ml) was added aqueous 2.5N KOH solution (3.3 ml, 8.34 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the organic phase was evaporated under reduced pressure. The mixture was cooled to 0 °C, neutralized with IN HCl and extracted with DCM (2x30 ml). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified by silicagel column chromatography by using 0-10% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.6 g, yield: 66.74%) as an off-white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 12.17 (s, 1H), 8.29 (s, 1H), 4.39-4.34 (m, 1H), 3.20-3.10 (m, 1H), 3.02-2.72 (m, 6H), 2.37-2.16 (m, 3H), 2.02-1.0 (m, 38H), 1.43 (s, 9H), 0.98-0.78 (m, 16H); ESI-MS: m/z 831.55 (M+Na) + .

Step 3: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-(2-am ino-2- methylpropanamido)ethyl)-l-isopropyl-5a,5b,8,8,lla-pentameth yl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid hydrochloride:

To (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-(2-((tert- butoxycarbonyl)amino)-2-methylpropanamido)ethyl)-l-isopropyl -5a,5b,8,8,l la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl)oxy)carbonyl)-2,2-dimethylcyclobut ane-l-carboxylic acid (step 2, 0.6 g, 0.741 mmol, 1.0 eq) in RB flask at 0 °C was added 4N HCl in 1,4-dioxane (12 ml). The reaction mixture was allowed to stir at room temperature for overnight. The mixture was evaporated under reduced pressure. The obtained compound was refluxed with acetonitrile (20 ml) for 30 minutes and filtered at hot condition. The solid was collected by filtration and dried under vacuum to obtain the title compound (0.025 g, yield: 4.5%) as an off-white solid.

1H NMR (300 MHz, DMSO-d 6 ): δ ppm 8.33 (t, = 5.1 Hz, 1H), 8.20 (br.s., 2H), 4.37-4.34 (m, 1H), 3.20-3.10 (m, 1H), 2.90-2.72 (m, 5H), 2.65-2.55 (m, 1H), 2.37-2.18 (m, 3H), 2.02- 1.0 (m, 28H), 1.41 (s, 6H), 1.27 (s, 3H), 0.95-0.78 (m, 16H); ESI-MS: m/z 709.5 (M+H) + . Example III-4: Preparation of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- ((4-chlorobenzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8 J la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahvdro-2H-cvclopentaralchrvsen- 9-yl)oxy)carbonyl)-2, -dimethylcyclobutane- 1-carboxylic acid hydrochloride:

Step 1: Synthesis of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-((tert- butoxycarbonyl)(4-chlorobenzyl) mino)ethyl)-l-isopropyl-5a,5b,8,8,lla-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl) ( lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate:

To a stirred solution of l-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2- aminoethyl)- l-isopropyl-5a,5b, 8,8,1 la-pentamethyl-2-oxo-

3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl) 3-benzyl (lS,3R)-2,2-dimethylcyclobutane-l,3-dicarboxylate (Example 4-step 4, 0.750 g, 1.05 mmol, 1.0 eq) in MeOH (22 ml) were added triethylamine (0.058 ml, 0.420 mmol, 0.4 eq), magnesium sulfate (0.189 g, 1.575 mmol, 1.5 eq) and 4-chlorobenzaldehyde (0.177 g, 1.26 mmol, 1.2 eq). The reaction mixture was stirred at room temperature for about 2 hours, then cooled to -5 °C and sodium borohydride (0.0159 g, 0.420 mmol, 0.4 eq) was added in small portions during 10 minutes. The reaction mixture was stirred at the same temperature for about 30 minutes, di-ie/ -butyl dicarbonate (0.29 ml, 1.260 mmol, 1.2 eq) was added, warmed to room temperature and stirred for about 1 hour. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice water (50 ml) and extracted with ethyl acetate (2x100 ml). The combined organic extracts were dried over Na 2 S0 4 , filtered and evaporated under reduced pressure to obtain the title compound (0.700 g, yield: 71%) as an off-white solid. 1H NMR (300 MHz, CDC1 3 ): δ ppm 7.35-7.27 (m, 7H), 7.13 (d, 2H), 5.14, 5.09 (ABq, JAB = 12.3 Hz, 2H), 4.44 (dd, / = 11.1, 4.5 Hz, 1H), 4.30-4.25 (m, 2H), 3.23-3.0 (m, 2H), 2.85-2.72 (m, 3H), 2.72-2.55 (m, 2H), 2.25-2.13 (m, 1H), 2.08-1.98 (m, 1H), 1.95-1.0 (m, 38H), 1.34 (s, 3H), 0.95 (s, 3H), 0.93 (s, 3H), 0.87 (s, 3H), 0.85 (s, 6H), 0.80-0.77 (m, 1H); ESI-MS: m/z 960.75 (M+Na) + .

Step 2: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,llaR,llbR,13aS)-3a-(2-((ter t- butoxycarbonyl)(4-chlorobenzyl)amino)ethyl)-l-isopropyl-5a,5 b,8,8,lla-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl)oxy)carbonyl)-2, -dimethylcyclobutane-l-carboxylic acid:

To a stirred solution of 1-benzyl 3-((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-

((tert-butoxycarbonyl)(4-chlorobenzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl- 2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H- cyclopenta[a]chrysen-9-yl) (lR,3S)-2,2-dimethylcyclobutane-l,3-dicarboxylate (step 1, 0.7 g, 0.745 mmol, 1.0 eq) in MeOH (7 ml) and THF (7 ml) was added aqueous 2.5N KOH solution (2.23 ml, 5.59 mmol, 7.5 eq). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure. The mixture was cooled to 0 °C, water (10 ml) was added, pU adjusted to 5.0 with IN HC1 and extracted with DCM (2x100 ml). The combined organic extracts were dried over sodium sulfate, filtered and evaporated under reduced pressure. The obtained solid was purified by silicagel column chromatography by using 0-5% MeOH in DCM gradient. The fractions containing the expected product were combined and concentrated under reduced pressure to obtain the title compound (0.400 g, yield: 63.2%) as an off-white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 7.29 (d, = 8.4 Hz, 2H), 7.14 (d, = 8.4 Hz, 2H), 4.46 (dd, = 11.4, 4.5 Hz, 1H), 4.30 (m, 2H), 3.16-3.02 (m, 2H), 2.86-2.75 (m, 3H), 2.65-2.52 (m, 2H), 2.38-2.29 (m, 1H), 2.28-2.12 (m, 1H), 2.12-1.0 (m, 38H), 1.34 (s, 3H), 0.97-0.77 (m, 16H); ESI-MS: m/z 870.7 (M+Na) + .

Step 3: Synthesis of (lR,3S)-3-((((3aR,5aR,5bR, 7aR,9S,llaR,nbR,13aS)-3a-(2-((4- chlorobenzyl)amino)ethyl)-l-isopropyl-5a,5b,8,8,lla-pentamet hyl-2-oxo- 3,3a,4,5,5a,5b,6,7, 7a,8,9,10,ll,lla,llb,12,13,13a-octadecahydro-2H-cyclopenta[a ]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid hydrochloride:

To a solution of (lR,3S)-3-((((3aR,5aR,5bR,7aR,9S,l laR,l lbR,13aS)-3a-(2-((tert- butoxycarbonyl)(4-chlorobenzyl)amino)ethyl)- l-isopropyl-5a,5b,8,8, 1 la-pentamethyl-2-oxo- 3,3a,4,5,5a,5b,6,7,7a,8,9,10,l l,l la,l lb,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen- 9-yl)oxy)carbonyl)-2,2-dimethylcyclobutane-l-carboxylic acid (step 2, 0.150 g, 0.176 mmol, 1.0 eq) in 1,4-dioxane (1.25 ml) was added 4N HC1 in 1,4-dioxane (3.75 ml). The reaction mixture was stirred at room temperature for overnight. After completion of the reaction (monitored by TLC), The reaction mixture was evaporated under reduced pressure. The residue was washed with MTBE (30 ml), followed by hexane (30 ml) to obtain the solid. To this solid compound, MTBE (30 ml) was added and refluxed for about 1 hour. The mixture was cooled to room temperature, solid was filtered, washed with MTBE (20 ml) and dried under vacuum to obtain the title compound (0.065 g, yield: 46.8%) as an off-white solid. 1H NMR (300 MHz, DMSO-d 6 ): δ ppm 12.06 (s, 1H), 8.96 (br.s., 2H), 7.52 (m, 4H), 4.40-4.33 (m, 1H), 4.13 (m, 2H), 3.20-3.07 (m, 2H), 2.84-2.65 (m, 5H), 2.38-1.02 (m, 34H), 0.98-0.77 (m, 16H); ESI-MS: m/z 748.60 (M+H) + .

The below compounds were prepared by procedure similar to the one described in General synthetic procedure C with appropriate variations in reactants, quantities of reagents and reaction conditions. The physiochemical characteristics of the compounds are summarized herein below table.

111.21 744.51

OH

111.22 792.48

OH

111.23 715.50

OH

111.24 715.50

OH

111.25 782.49

OH

111.26 794.54

OH

111.27 715.50

OH

ı63

III.115 747.49

OH

III.116 746.49

OH

III.117 768.49

OH

III.118 844.52

OH

III.119 782.50

OH

III.120 813.53

OH

III.139 734.53

OH

III.140 691.48

OH

III.141 720.51

OH

III.142 833.52

OH

III.143 833.52

OH

III.144 796.40

OH III.145 833.52

OH

III.146 833.52

OH

III.147 742.50

OH

III.148 796.47

OH

III.149 808.52

OH

III.150 729.48

OH III.228 919.55

OH

III.229 920.58

OH

III.230 960.62

OH

III.231 820.61

OH

III.232 870.56

OH

III.233 693.51

OH

III.234 735.56

OH III.284 707.53

OH

III.285 709.51

OH

III.286 814.57

OH

Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as described above. All publications and patent applications cited in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.




 
Previous Patent: EXTENDED RELEASE OSMOTIC DOSAGE FORM COMPRISING HIGH METHYLPHENIDATE HYDROCHLORIDE LOAD

Next Patent: METHOD FOR PRODUCING COPPER NANOPARTICLES AND USE OF SAID PARTICLES